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ABSTRACT 
Kate Lynn White: Identification of Biased Kappa Opioid Receptor Ligands For In Vivo 
Probing of Specific Signal Transduction Pathways 
(Under the direction of Dr. Bryan L. Roth) 
The κ opioid receptor (KOR)-dynorphin system has been implicated in the control of 
affect, cognition, motivation, and is thought to be dysregulated in mood and psychotic disorders, 
as well as in various phases of opioid dependence. KOR agonists exhibit analgesic effects but the 
adverse effects produced by KOR agonists, including sedation, dysphoria, and hallucinations 
have limited their clinical use. Interestingly, KOR-mediated dysphoria, assessed in rodents as 
aversion, has recently been attributed to the activation of the p38 MAPK pathway following 
arrestin recruitment to the activated KOR. Therefore, KOR-selective G protein biased agonists, 
which do not recruit arrestin, have been proposed to be more effective analgesics, without the 
adverse effects triggered by the arrestin pathway. As an initial step toward identifying novel 
biased KOR agonists, we applied a multi-faceted screening strategy utilizing both in silico and 
parallel screening approaches. We identified several KOR-selective ligand scaffolds with a range 
of signaling bias in vitro. The arylacetamide-based scaffold includes both G protein and β-
arrestin-biased ligands, while the endogenous peptides and the diterpene scaffolds are G protein-
biased. Interestingly, we found scaffold screening to be more successful than library screening in 
identifying biased ligands. Many of the identified functionally selective ligands are potent 
selective KOR agonists that are active in the central nervous system. Therefore, we sought to 
determine if G protein-biased ligands have therapeutic potential by assessing β-arrestin 2 KO 
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mice and KOR-selective biased ligands in multiple behavioral paradigms. We found that KOR-
mediated G protein signaling induces analgesia and aversion, while β-arrestin 2 signaling causes 
motor incoordination. Additionally, unlike unbiased KOR agonists, the G protein-biased ligand 
RB 64 does not induce sedation and anhedonia-like effects, suggesting that a signaling 
mechanism other than G protein signaling mediates these effects. These studies suggests that 
many of the negative side effects of KOR agonism can be alleviated with the use of KOR-
selective G protein-biased ligands.  
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CHAPTER 1: BACKGROUND 
1.1 INTRODUCTION 
G protein-coupled receptors (GPCRs) are a superfamily of seven transmembrane 
receptors involved in transmitting diverse extracellular signals allowing cells to sense and adapt 
to their environment. There are more than 800 members within the human GPCR superfamily, 
and they are widely expressed throughout the human body and involved in a number of disease 
states (Fredriksson et al., 2003). Additionally, these receptors are targeted by approximately 30% 
of marketed drugs and represent about 4% of the human genome (Hopkins and Groom, 2002). 
The three major classes of GPCRs are the rhodopsin-like receptors (class A), the secretin 
receptors (class B), the metabotropic glutamate receptors (class C), and the frizzled/smoothened 
receptors (class F). Furthermore, recent advances in our understanding of GPCR signaling have 
revalidated many GPCR targets for therapeutics with fewer side effects. Classically, the GPCR 
signaling transducers are G proteins (Gα and Gβγ), and after activation the receptor is 
phosphorylated by G protein receptor kinases (GRKs) which recruits β-arrestins leading to 
desensitization and internalization of the receptor (Gilman, 1987; Lohse et al., 1990).  
More recently it has been appreciated that GPCRs can interact with and signal through 
non-G protein effectors. In addition to mediating receptor desensitization and internalization, β-
arrestins can also mediate G protein-independent signaling cascades (Lefkowitz and Shenoy, 
2005). β-arrestin signaling has been shown to have broad effects on cellular function, from 
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activating mitogen-activated protein kinases (MAPKs) to altering protein synthesis (DeWire et 
al., 2008). Furthermore, different GRK subtypes have been shown to induce unique regulatory 
functions. For example, the V2 vasopressin receptor (V2R) mediated β-arrestin-dependent ERK 
activation is regulated by GRK5 and GRK6, and second messenger signaling is negatively 
regulated by GRK2 (Ren et al., 2005). This observation led to the hypothesis that GRK mediated 
phosphorylation of the C-terminal tail of GPCRs generates a phosphorylation “barcode” that 
dictates interactions with effector proteins and the pattern of subsequent signaling (Nobles et al., 
2011). GPCRs represent successful drug targets, and increasing the understanding of the 
mechanisms and functional effects of GPCR activation might aid in more effective and safer 
therapies. 
  
1.2 GPCR STRUCTURE AND FUNCTION 
In 2000, the first high-resolution structure of a mammalian GPCR was obtained (bovine 
rhodopsin) (Palczewski et al., 2000). The past decade has been a “golden era” for GPCR 
structural studies that began with a key collaboration between the labs of Brian Kobilka at 
Stanford University and Ray Stevens at Scripps. Kobilka’s detailed knowledge of the β2AR and 
the technological advances developed in the Steven’s lab allowed for the solution of the structure 
of the crystalized β2AR in 2007 (Cherezov et al., 2007; Rosenbaum et al., 2007). Since then, the 
rate of solving GPCR structures has greatly increased, with 9 structures solved in 2012, and 6 
more solved in 2013. The 2012 Nobel Prize was awarded to Robert Lefkowitz and Brian Kobilka 
for their contributions to the understanding of GPCR structure and function (Kenakin, 2013). 
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GPCRs, like all proteins, are highly dynamic and adopt changing conformations. GPCR 
binding partners stabilize certain conformations that select for interactions with specific binding 
partners, affecting signaling pathways. These binding partners include ligands, G proteins, and 
arrestins (Kenakin, 2002; Nygaard et al., 2013; Yan et al., 2008). Unbound receptors fluctuate 
between active and inactive states, allowing for basal signaling, and inverse agonists stabilize the 
receptor in a rigid inactive state to prevent signaling (Nygaard et al., 2013). Agonist binding 
leads to small conformational changes within the binding pocket that translate to larger changes 
in the intracellular region of the transmembrane helices, which allow for interactions with 
intracellular signaling proteins (Katritch et al., 2013; Liu et al., 2012; Ranganathan et al., 2012). 
The most pronounced helical rearrangement during receptor activation involves a large 
“swinging” effect of transmembrane VI (TM VI) and movements of TM V, and this 
rearrangement is most pronounced in the β2AR-Gα complex (Katritch et al., 2013; Rasmussen et 
al., 2011).  
Several conserved microswitches have been identified in GPCR activation. The D[E]RY 
motif in TM III is highly conserved in class A GPCRs (rhodopsin-like GPCRs). Asp
3.50
 forms a 
salt bridge to Asp(Glu)
3.49
, and this salt bridge is broken only in the β2AR-Gα structure. In this 
case, the C-terminal helix of the Gα subunit interacts with Asp3.50, inducing a rotamer change, 
suggesting that the G protein is necessary for this switch (Katritch et al., 2013). Additionally, the 
NPxxY motif in TM VII contains a highly conserved Tyr
7.53
 that functions as an activation 
switch (Nygaard et al., 2009). Upon receptor activation, the intracellular end of TM VII moves 
towards the receptor core, and Tyr
7.53
 undergoes a rotamer switch. An additional motif, the PIF 
motif, was recently identified (Wacker et al., 2013). This motif consists of P
5.50
, I
3.40
, and F
6.44
, 
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and these residues are clustered together in the center of the GPCR below the binding pocket. 
These microswitches are involved in ligand-induced conformational changes in the binding 
pocket that translate to larger intracellular rearrangements and activation. 
Different ligands stabilize different GPCR conformations, causing unique signaling 
effects (Liu et al., 2012; Nygaard et al., 2013). Certain ligands can stabilize partially activated 
conformations that allow for the activation of a subset of downstream signaling effects (Liu et 
al., 2012; Ranganathan et al., 2012; Wacker et al., 2013) (Fig. 1.1). This phenomenon is known 
as “functional selectivity” or “biased signaling” (Kenakin, 2011; Urban et al., 2007). Numerous 
ligands exhibit G protein or β-arrestin biased (Allen et al., 2011). The G protein-biased ligands 
mediate conformational movements of TM VI, and the β-arrestin-biased ligands mediate 
movements in TM VII (Liu et al., 2012). Further structural mechanisms of functional selectivity 
were revealed by the structures of the 5HT1B and 5HT2B receptors in complex with ergotamine, 
which is a β-arrestin biased ligand for the 5HT2B receptor. Comparing the structures of these 
receptors revealed distinct differences in the conformation of TM VI and TM VII. TM VI in the 
5HT1B receptor is in a more active conformation than in the 5HT2B receptor, and TM VII is in a 
more pronounced active state in the 5HT2B receptor than in the 5HT1B receptor (Wacker et al., 
2013). The PIF motif is in a partially activated conformation in the 5HT2B receptor and in a fully 
active conformation in the 5HT1B receptor, suggesting a possible role of this motif in mediating 
the biased signaling of ergotamine in the 5HT2B receptor (Wacker et al., 2013).  
Currently many labs are attempting to understand the molecular mechanisms of 
functional selectivity and the potential therapeutic effects of selectively stimulating a subset of 
downstream effectors. The promise of functionally selective ligands has revitalized many GPCR 
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targets for a wide range of therapeutics with the promise of greater therapeutic efficacy and 
fewer side effects. Multiple studies have suggested that the anti-psychotic effects of dopamine D2 
receptor agonists are mediated by β-arrestin signaling (Allen et al., 2011; Klewe et al., 2008; 
Masri et al., 2008; Urs et al., 2012). There are several functionally selective ligands in clinical 
trials for a number of disease states: acute heart failure (angiotensin II 1a receptor), postoperative 
pain (mu opioid receptor (MOR)), and moderate to severe pain (delta opioid receptor (DOR)) 
(Allen et al., 2011; DeWire et al., 2013; Monasky et al., 2013; Pradhan et al., 2011; Whalen et 
al., 2011). A detailed review of current targets for biased ligand therapies was compiled by 
Whalen et al., 2011. 
The entire opioid family is being investigated for functionally selective therapies because 
of the receptors roles in physiology, and the structures of all four family members in complex 
with an antagonist were recently solved (Granier et al., 2012; Manglik et al., 2012; Thompson et 
al., 2012; Wu et al., 2012). Combining this structural information with mutagenesis and 
functional studies should provide insight into the molecular mechanism of specific pathway 
activation and aid in designing biased ligands to test in vivo. 
 
1.3 THE OPIOID FAMILY OF GPCRS 
GPCRs in the opioid family are central targets for biased ligand therapy research. Opiates 
are natural compounds, such as morphine, that are found in the opium poppy. The opioid 
receptors are the main sites of actions of opiates and endogenous opioid peptides. This family 
consists of MOR, DOR, the kappa opioid receptor (KOR), and the nociception/orphanin FQ 
peptide receptor (NOP). MOR and KOR were named after the original drugs that were found to 
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bind and activate the receptors, morphine and ketocyclazocine (Gilbert and Martin, 1976; Lord 
et al., 1977), and DOR was named based on its discovery in the mouse vas deferens (Lord et al., 
1977). The NOP was originally an orphan receptor and was classified as an opioid receptor based 
on high sequence homology (Henderson and McKnight, 1997). The opioid receptors are 
expressed widely throughout the central nervous system (CNS) and periphery, where they 
mediate nociception and analgesia (Goldstein et al., 1971; Mansour et al., 1988; Pert and Snyder, 
1973). Opioid receptors regulate many physiological functions in addition to pain perception and 
analgesia. MOR activation can cause respiratory depression, euphoria, and addiction, and it can 
impact immune functions and gastrointestinal motility (Dhawan et al., 1996). DOR activation 
can cause physical dependence, convulsions, and anti-depressant effects (Broom et al., 2002). 
KOR agonists cause hallucinations, dysphoria, anticonvulsant effects, diuresis, and 
neuroprotection, but they have a low abuse potential (Ranganathan et al., 2012; Roth et al., 2002; 
Schunk et al., 2011; Schwarzer, 2009). NOP activation cause anxiolysis, depression, and anxiety 
effects, and it alter learning, memory, and immune responses (Lambert, 2008).  
The opioid receptors couple to the Gαi/o subtype of G proteins and inhibit adenylyl 
cyclases, leading to decreased cAMP production (Childers and Snyder, 1978; Minneman and 
Iversen, 1976) (Hsia et al., 1984). After activation, the Gβγ subunit dissociates from the Gα 
subunit and activates GIRK channels (G protein-coupled inwardly-rectifying potassium 
channels) (Wickman and Clapham, 1995) causing hyperpolarization and mediating the inhibitory 
effects of opioids on neurons (Torrecilla et al., 2002). The Gβγ subunit also interacts with Ca+2 
channels, leading to reduced Ca
+2
 currents (Grudt and Williams, 1995).  
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Decreases in cAMP production have been shown to attenuate the activity of cAMP-
dependent PKA resulting in reduced neurotransmitter release (Chavez-Noriega and Stevens, 
1994; Greengard et al., 1991). Opioid receptors have been found to inhibit the release of 
glutamate and γ-aminobutyric acid (GABA) and have been found to have, overall, inhibitory 
effects on the CNS (Williams et al., 2001). However, opioid receptors have different effects on 
physiology because of differing expression patterns and unique inputs on certain brain regions 
(Wee and Koob, 2010). For example, MOR and KOR cause opposing effects on the reward 
circuitry. The rewarding effects of MOR agonists are thought to be mediated by a release of 
dopamine in the brain, while KOR agonists cause an inhibition in dopamine release leading to 
aversion (Di Chiara and Imperato, 1988; McLaughlin et al., 2003a; Zimmer et al., 2001).  
Opioid receptors are regulated by endogenous opioid peptides. The first two identified 
peptides that activate both MOR and DOR were [Met]-enkephalin and [Leu]-enkephalin, which 
both originate from the precursor protein proenkephalin (Hughes et al., 1975; Noda et al., 1982). 
Multiple opioid peptides and precursor peptides were later identified in the human brain. 
Proopiomelanocortin (POMC) was identified as the precursor for β-endorphin, which activates 
MOR and DOR (Cox et al., 1976). The human prodynorphin gene was found to be the precursor 
for the peptides dynorphin A, dynorphin B, α-neo-endorphine, and β-neo-endorphine, which can 
activate MOR and DOR, but most potently activate KOR (Chavkin et al., 1982; Goldstein et al., 
1981; Horikawa et al., 1983). Pronociceptin is the precursor for nociception, and both 
nociception and orphanin-FQ activate the NOP (Mollereau et al., 1996; Reinscheid et al., 1995). 
These peptides, along with their cognate receptors, are subject to genetic regulation. 
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Polymorphisms of opioid peptides and receptor genes are associated with a higher risk of drug 
abuse and psychiatric disorders (Butelman et al., 2012; Tejeda et al., 2012).  
 
1.4 THE KAPPA OPIOID RECEPTOR 
This dissertation focuses on KOR as a potential therapeutic target for analgesics that have 
low potentials for dependence and abuse. The KOR/dynorphin system is involved in many 
stress-induced behaviors, including anxiety, addiction, and depression, and in multiple disease 
states, such as psychiatric diseases and epilepsy (Sheffler and Roth, 2003; Tejeda et al., 2012; 
Tortella et al., 1986). KOR agonists have been reported to cause psychotomimesis and 
hallucinations (Pfeiffer et al., 1986; Roth et al., 2002). Originally, these hallucinations were 
thought to be mediated by off-target effects, but in 2002 the hallucinogenic component of salvia 
divinorum, named salvinorin A (sal A), was found to selectively interact with KOR (Roth et al., 
2002). Prior to this study, the only receptor reported to mediate hallucinations was the 5HT2A 
receptor, which is activated by LSD (Nichols, 2004). This finding solidified the role of KOR in 
mediating consciousness and the perception of reality, and provided additional avenues for 
treating cognitive disease states such as Alzheimer’s Disease and schizophrenia (Vortherms and 
Roth, 2006). The effects of KOR activation on cognition remain relatively unexplored compared 
with the wealth information regarding the role of KOR in drug abuse and mood disorders.   
KOR agonists cause depressive-like effects, and KOR antagonists cause antidepressant-
like effects in animals (Carlezon et al., 2006; Todtenkopf et al., 2004; Wee and Koob, 2010). 
These effects have been attributed to KOR-mediated inhibition of synaptic transmission in 
regions that have been shown to regulate reward. For example, KOR agonists decreases 
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dopamine release in the nucleus accumbens (NAc), contributing to depressive-like behaviors 
(Ebner et al., 2010; Markou and Koob, 1991). Furthermore, after chronic drug abuse, the actions 
of the endogenous KOR system cause a decrease in dopamine in the NAc, contributing to 
subsequent depressive-like effects (Knoll and Carlezon, 2009). KOR activation decreases 
dopamine release in the ventral tegmental area (VTA), which is associated with the negative 
reinforcement of drug dependence (Trifilieff and Martinez, 2013; Wee and Koob, 2010). Stress-
induced corticotropin-releasing factor (CRF) causes dysphoria and drug relapse by activating the 
dynorphin system (Bruchas et al., 2009; Land et al., 2008). KOR activation also mediates 
synaptic transmission in brain regions that regulate affective behavior, such as the bed nucleus of 
the stria terminalis (BNST) (Li et al., 2012). These studies suggest an unambiguous role of the 
KOR/dynorphin system in stress response and depressive-like behaviors. For this reason, KOR 
antagonists are being investigated as potential anti-drug abuse and anti-depressive therapeutics. 
KOR activation also induces analgesia with a low abuse potential, providing an additional 
analgesic drug target, but KOR agonists are limited as analgesic therapies because they cause 
dysphoria and hallucinations (Ansonoff et al., 2006; Pfeiffer et al., 1986; Ranganathan et al., 
2012). 
Recent efforts have begun to understand how certain KOR-dependent signaling cascades 
mediate the diverse effects of KOR agonism. As previously mentioned, KOR couples to Gαi/o 
subunits, leading to decreased cAMP levels. Once activated, the receptor is phosphorylated by 
GRK3 and then internalized after β-arrestin 2 recruitment (Appleyard et al., 1999). KOR 
stimulation leads to the activation of ERK1/2 through G protein and β-arrestin-dependent 
mechanisms (McLennan et al., 2008). KOR activation also leads to p38MAPK activation, which 
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was found to be mediated by GRK3 phosphorylation and arrestin recruitment in primary neurons 
and astrocytes (Bruchas et al., 2006). A single point mutation (S369A) in the C-terminal tail of 
the rat KOR was found to prevent GRK3 phosphorylation and receptor desensitization 
(McLaughlin et al., 2003b). p38 MAPK activation is absent upon activation of S369A KOR, 
presenting a potential  approach for understanding the role of p38 MAPK in KOR mediated 
behaviors (Bruchas et al., 2006). This receptor mutant was shown to mediate aversion and stress-
induced reinstatement of drug seeking, but did not have an effect on analgesia (Land et al., 
2009). This suggested a potential role of KOR-dependent p38 MAPK activation in regulating 
some of the negative side effects of KOR activation, but did not explain the analgesic effects 
(Fig. 1.2). These results are consistent with the blocking effects of pertussis toxin on KOR-
induced analgesia (Goicoechea et al., 1999; Gullapalli and Ramarao, 2002), and a recent study 
showed that a KOR selective G protein biased ligand induces analgesia (Zhou et al., 2013). This 
initial evidence suggests that KOR-selective G protein biased ligands might have potential as 
analgesics that do not induce unwanted side effects. However, the effects of KOR biased ligands 
on dysphoria, stress, anhedonia, sedation, and cognition are unknown.  
The research presented in this dissertation aims to understand how certain KOR signaling 
cascades mediate specific behaviors. I first identified KOR biased ligands using a multifaceted 
screening strategy utilizing both in silico and parallel screening approaches. I also probed select 
KOR-mediated signal transduction pathways in vivo using β-arrestin 2 KO mice and a KOR G 
protein biased ligand to further understand the effects of G protein and β-arrestin 2 signaling in 
mediating analgesia, aversion, sedation, and anhedonia. Portions of the concepts discussed in this 
chapter are repeated in subsequent chapters to increase clarity in this dissertation. 
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Adapted from (Vardy and Roth, 2013) 
 
Figure 1.1: Dynamic nature of GPCR conformations 
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Figure 1.2 : KOR mediated cellular signaling and hypothesized behavioral outcomes 
Adapted from (Bruchas and Chavkin, 2010)
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CHAPTER 2: IDENTIFICATION OF NOVEL FUNCTIONALLY SELECTIVE 
KAPPA OPIOID RECEPTOR SCAFFOLDS
1
 
2.1 INTRODUCTION AND RATIONALE 
The kappa opioid receptor (KOR)-dynorphin system has been implicated in the 
pathogenesis and pathophysiology of affective disorders, drug addiction, and psychotic disorders 
(Bruchas and Chavkin, 2010; Sheffler and Roth, 2003). KOR and dynorphin are highly 
expressed in regions of the brain implicated in the modulation of reward, mood, cognition and 
perception (ventral tegmental area, nucleus accumbens, prefrontal cortex, hippocampus, striatum, 
amygdala, and hypothalamus) (Knoll and Carlezon, 2009; Land et al., 2008; Schwarzer, 2009; 
Tejeda et al., 2012). Accordingly, drugs directed at KOR as antagonists or partial agonists have 
potential utility for a number of indications--especially as antidepressants and anxiolytics 
(Carlezon et al., 2009). Additionally, KOR agonists are gaining attention as potential analgesics 
without a high abuse potential (Prevatt-Smith et al., 2011; Tao et al., 2008; Wee and Koob, 
2010). However, the adverse effects produced by many centrally-active KOR agonists, including 
sedation, dysphoria, and hallucinations, have limited their clinical development (Pfeiffer et al., 
1986). Dysphoria has been considered the best surrogate marker of KOR agonism, while the 
                                                 
1
 This chapter, except Fig. 2.3, was previously published in Molecular Pharmacology. The original citation is as 
follows:  
White, K.L., Scopton, A.P., Rives, M.L., Bikbulatov, R.V., Polepally, P.R., Brown, P.J., Kenakin, T., Javitch, J.A., 
Zjawiony, J.K., and Roth, B.L. (2014). Identification of novel functionally selective kappa-opioid receptor scaffolds. 
Mol Pharmacol 85, 83-90. 
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hallucinogenic effects of KOR agonists have been relatively unexplored, except in the case of sal 
A (Roth et al., 2002; White and Roth, 2012).  
KOR stimulation leads to the activation of the canonical Gαi signaling cascade, the 
recruitment of β-arrestin and activation of p38 MAPK and an array of other downstream 
effectors (Appleyard et al., 1997; Bruchas et al., 2006; Land et al., 2009). It has been 
hypothesized that the dysphoric effects of KOR agonism are mediated through the arrestin-
dependent activation of p38 MAPK, while the analgesic effects of KOR agonism are mediated 
only through G protein signaling (Bruchas et al., 2007a). This suggests the potential for 
functionally selective ligands of KOR as analgesics devoid of dysphoric effects. Ligands that 
differentially stimulate canonical and non-canonical transduction pathways are considered to be 
“functionally selective” (Urban et al., 2007), and their differential engagement in signaling is 
referred to as ‘biased’. Identifying functionally selective KOR agonists with extreme signaling 
bias will be useful for determining which signal transduction pathways are important for 
therapeutic efficacy and which signaling cascades contribute to the side effects (Allen et al., 
2011). Due to the diverse structure of KOR ligands, there is the potential to discover a variety of 
functionally selective ligands that can be used to probe KOR signaling, as well as to improve 
KOR-based therapeutics. The goal of this study was to identify a range of chemotypes of 
functionally selective KOR ligands using a parallel in vitro screening approach accompanied by 
in silico selection. 
KOR agonists can be classified into five chemotypes: the endogenous peptides 
(dynorphins), the benzodiazepines (tifluadom), the benzomorphans (ketazocine), the 
arylacetamides (U69593), and the diterpenes (sal A). Dynorphins have been implicated in 
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addiction and drug seeking, mood disorders, and the stress response (Bruchas and Chavkin, 
2010). The benzomorphans, such as bremazocine, have limited KOR selectivity but show strong 
analgesic effects. However, despite their low dependence potential, they were removed from 
clinical development due to psychotomimetic and dysphoric effects (Dortch-Carnes and Potter, 
2005). It was originally thought that the negative side effects of KOR agonists were due to off-
target effects and a new class of selective KOR agonists—the arylacetamide derivatives such as 
U69593—was developed to circumvent these potential shortcomings. However, some 
arylacetamides are also reported to produce hallucinations and aversion (Millan, 1990). The 
diterpenes, represented by sal A (which is the main psychoactive compound in S. divinorum), 
represent a novel scaffold of highly potent and selective KOR agonists with no appreciable 
affinity for any other known neurotransmitter system or receptor (Roth et al., 2002).  
Functionally selective ligands at other targets have been identified by screening 
derivatives of known ligand scaffolds in a parallel fashion, in which libraries of analogues are 
screened simultaneously against multiple downstream effector pathways (see for instance (Allen 
et al., 2011; Chen et al., 2012; Huang et al., 2009; Wacker et al., 2013). The extent of functional 
selectivity of those compounds, or bias factor, can be quantified using the operational model 
(Leff and Black) (Kenakin and Christopoulos, 2013; Kenakin et al., 2012; Wacker et al., 2013). 
Accordingly, we sought to identify and quantify the degree of bias for representative scaffolds 
that maintain high affinity and selectivity for KOR.  
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2.2  METHODS 
Drugs 
 The National Institutes of Health Clinical Collection (NCC) library used here is a 
publicly available library consisting of Food and Drug Administration–approved drugs we have 
previously used to identify biologically active drugs (Huang et al., 2011; Huang et al., 2009). 
The synthesis of the RB family of salvinorin derivatives used here has been previously 
described: 22-chlorosalvinorin A (RB 48), 22-thiocyanatosalvinorin A (RB 64), 22-
bromosalvinorin A (RB 50), (22R,S)-22-chloro-22-methylsalvinorin A (RB-55), (22S)-22-
chloro-22-methylsalvinorin A (RB 55-1), (22R)-22-chloro-22-methylsalvinorin A (RB-55-2), 
22-cyanosalvinorin A (RB 59), and 22-methoxysalvinorin A (RB 65). (Yan et al., 2009) Sal A 
was isolated from dried leaves of Salvia divinorum purified as previously reported (Kutrzeba, 
2009) and hydrolyzed to salvinorin B, which was a starting material for the synthesis of all 
analogs.  
Dynorphin 1-13, Dynorphin 1-11, Dynorphin 1-9, Dynorphin 1-8 are all obtained from 
NIDA drug supply program. (+)-(5α,7α,8β)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-
8-yl]-benzeneacetamide (U69693), (±)-(5α,7α,8β)-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-
1-oxaspiro[4.5]dec-8-yl]benzeneacetamide mesylate salt (Spiradoline, U62066), 17-
cyclopropylmethyl-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2',3'-indolomorphinan 
(Naltrindole), L-N-cyclobutylmethyl-3,14-dihydroxymorphinan (+)-tartrate salt (Butorphanol), 
and 17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride hydrate 
(Nalbuphine) were purchased from Sigma-Aldrich. 4-[(3,4-Dichlorophenyl)acetyl]-3-(1-
pyrrolidinylmethyl)-1-piperazinecarboxylic acid methyl ester fumarate salt (GR89696), 2-(3,4-
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dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide hydrochloride 
(ICI199,441), trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-
pyrrolidinyl)cyclohexyl]benzeneacetamide hydrochloride ((-)-U50,488), trans-(+)-3,4-dichloro-
N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide hydrochloride ((+)-U50,488), 2-
(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)-
ethyl]acetamide hydrochloride (DIPPA), (±)-1-(3,4-dichlorophenyl)acetyl-2-(1-
pyrrolidinyl)methylpiperidine hydrochloride (BRL 52537), N-methyl-N-[(1S)-1-phenyl-2-(1-
pyrrolidinyl)ethyl]phenylacetamide hydrochloride (N-MPPP), (RS)-[3-[1-[[(3,4-
dichlorophenyl)acetyl]methylamino]-2-(1-pyrrolidinyl)ethyl]phenoxy]acetic acid hydrochloride 
(ICI 204,448), and Dynorphin A were purchased from Tocris. 3-(Cyclopropylmethyl)-6,11-
dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol (Cyclazocine) and (5α,7α)-17-
(cyclopropylmethyl)- 4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α,α-dimethyl-6,14-
ethenomorphinan-7-methanol (Diprenorphine) were acquired from the NIDA drug supply 
program.  
The synthesis of N-naphthoyl-beta-naltrexamine (β-NNTA), 6'-guanidino-17-
(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,14-dihydroxyindolo[2',3':6,7]morphinan (6'-
GNTI), and 5'-Guanidino-17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,14-
dihydroxyindolo[2',3':6,7]morphinan (5'-GNTI) as previously described (White et al., 2014).  
Measurement of G protein activation 
A genetically engineered firefly luciferase cAMP biosensor (GloSensor; Promega) was 
used to quantify Gi-mediated activity as described previously (Allen et al., 2011; Chen et al., 
2012; Thompson et al., 2012; Wacker et al., 2013; Wu et al., 2012). Details are available on-line 
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at the NIMH Psychoactive Drug Screening Program site 
(http://pdsp.med.unc.edu/PDSP%20Protocols%20II%202013-03-28.pdf). In brief, HEK cells 
were transfected with the biosensor and KOR at a 1:1 ratio. The next day, the cells were plated 
into Greiner white 384-well plates (catalog # 655098). The cells were incubated with the test 
compound for 20-30 minutes before addition of the GloSensor
TM
 reagent (luciferin) and 
isoproterenol (Allen et al., 2011). Luminescence is quantified 10 minutes after the addition of 
GloSensor
TM reagent and isoproterenol. The Z’ score for this assay using sal A is 0.89 (Zhang et 
al., 2000). 
Measurement of arrestin recruitment 
Two assays were used to assess β-arrestin translocation: the Tango assay as described 
previously (Barnea et al., 2008; Wu et al., 2012) and a bioluminescence resonance energy 
transfer (BRET)-based assay as an orthologous confirmatory assay as described previously 
(Rives et al., 2012). The Tango assay requires the fusion of a transcription factor to the C-
terminus of KOR via linker that contains a TEV protease cleavage site. Activation of KOR leads 
to the recruitment of β-arrestin 2 fused with TEV protease, which releases the transcription 
factor, making it available for induction of luciferase expression. The BRET assay requires co-
transfection of KOR fused with renilla luciferase, venus tagged β-arrestin 2, and GRK 2 and the 
cells were distributed on 96-well plates one day prior to assay. The Z’ scores using sal A are 
0.716 and 0.95 for the Tango assay and the BRET assay, respectively. 
Virtual screening for biased ligands 
 Upon identification of a potential scaffold with signaling bias, we then identified 
analogues as detailed previously (Huang et al., 2011) using the ZINC database (Irwin and 
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Shoichet, 2005; Irwin et al., 2012). Compounds identified were purchased and screened as 
described above. 
Quantifying Bias 
 We used the method developed by Kenakin and Christopolous to quantify the biased 
signaling of ligands (Kenakin and Christopoulos, 2013; Kenakin et al., 2012).  After generating 
concentration-response curves, we fit the data to a mathematical model based on the Black and 
Leff Operational model to generate log(/KA) values. The log(/KA) value is a transduction 
coefficient that represents the affinity and efficacy of a ligand for a specific signaling pathway, in 
this case either G protein activation or arrestin mobilization. This model also incorporates the 
receptor density and coupling within a system, and therefore is receptor expression independent. 
The log(/KA) of each test ligand is then compared to the log(/KA) of a reference ligand, in this 
case sal A, for both G protein activation and arrestin recruitment.  Sal A was chosen as the 
reference ligand because it has very similar EC50 values for both the G protein and arrestin 
pathways and it also displays full efficacy at both pathways. Because agonists activate different 
signaling pathways with different efficacies and potencies, ligand bias is quantified by 
comparing the activity of an agonist in one assay to their relative activity in another assay, using 
the same reference ligand in both assays. This method reduces observation or assay bias, as well 
as system bias innate to the assays used (Kenakin and Christopoulos, 2013). Generating a single 
number that incorporates agonist affinity and efficacy is useful for identifying which ligands to 
use in future studies.  
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2.3  RESULTS 
2.3.1 In Parallel Screening 
To identify KOR ligands with signaling bias, we screened in parallel the NCC library of 
approved medications at a concentration of 3 μM using a split luciferase cAMP assay 
(GloSensor) and a genetically encoded arrestin recruitment assay (Tango). Seven “actives” from 
this screen were further analyzed by full concentration-response studies (Figure 2.1 and Table 
2.1). GR89696 was the only compound from the NCC library identified as a potent biased ligand 
for KOR (Table 2.1). The concentration-response analyses of “actives” from the NCC library 
screen yielded two low-potency agonists: 2-(2-aminoethyl)-pyridine and N-cyano-N9-(1,1-
dimethylpropyl)-N99-3-pyridinylguanidine. Because few compounds in this library were known 
or predicted to bind to KOR, we continued our screening efforts with scaffolds known to have 
affinity for KOR. We focused on screening scaffold derivatives of arylacetamides, dynorphins, 
morphinans, benzomorphans, and salvinorins. Tables 2.2–2.6 depict the potencies and efficacies 
of these ligands for G protein activation and arrestin mobilization (Tango) as well as the 
calculated bias factors.  
 
2.3.2 Functional Analysis and Bias Factor Quantification 
All the arylacetamides tested are potent agonists at KOR with varying degrees of bias 
(Table 2.2). ICI 204,448 and BRL 52537 were identified from a virtual screen using the ZINC 
database (Irwin and Shoichet, 2005; Irwin et al., 2012) as potentially biased ligands based on the 
structure of GR89696. GR89696 and ICI 199,441 displayed modest arrestin bias (bias factors 5 
and 4, respectively) while ICI 204,448 and (-)-U50,488 are only very weakly biased for arrestin 
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(bias factors 2 for each compound). In contrast, U62066 and (+)-U50,488 are slightly G protein–
biased (bias factors 6 and 8, respectively). Lastly, we found that U69593, DIPPA, N-MPPP, and 
BRL 52537 are all unbiased agonists. 
The dynorphin peptides tested displayed varying degrees of G protein bias (Table 2.3). 
Dyn A, Dyn 13, and Dyn 1-11 have the highest degree of bias (34, 34, and 44, respectively), 
while Dyn 1–8 and Dyn 1–9 are more moderately biased (4 and 16, respectively). This represents 
the first report of endogenous KOR ligands having a biased signaling profile relative to sal A, 
which equally stimulates G protein and arrestin pathways. Furthermore, the morphinans (Table 
2.4) and benzomorphans (Table 2.5) tested displayed very little bias. Only 6’-GNTI displayed a 
slight G protein bias (bias factor of 6), consistent with previous studies (Rives et al., 2012; 
Schmid et al., 2013). Also, we found that the antagonist JDTic has no agonist activity in either G 
protein or arrestin assays (Table 2.5). 
 Additionally, we tested several C-2–modified salvinorin derivatives and found them to 
display a wide range of G protein bias (Table 2.6). Of this family, RB 64 and RB 48 are the most 
potent in activating G protein signaling and have a high degree of bias (35 and 25, respectively). 
RB 59, RB 55-2, and RB 50 also have high G protein bias factors (95, 33, and 69, respectively). 
RB 55-1 and RB 65 are lower potency ligands but still have a strong bias (bias factors 22 and 29, 
respectively). RB 55 has a slight bias factor of 8, while salvinorin B, a metabolite of sal A, has a 
bias factor of 4. 
 Figure 2 depicts the G protein activation (Fig. 2.2A) and arrestin mobilization (Fig. 2.2B) 
concentration-response curves for the compounds found to be the most potent and the most 
biased, along with relevant controls. The “bias plot” indicates the signaling bias of each 
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compound by showing the response in the arrestin recruitment assay as a function of the 
corresponding response in the G protein activation assay (Fig. 2.2C). Thus, ICI 199,441 and 
GR89696 are arrestin biased, whereas RB 64 and RB 48 are G protein biased. 
 
2.3.3  Orthologous Arrestin Recruitment Assay 
 To confirm our results from the Tango arrestin recruitment assay, we used a BRET-based 
arrestin-recruitment assay (Rives et al., 2012) to further analyze the compounds displaying the 
highest degree of bias. Sal A displayed very similar potency values for the Tango and BRET 
assays (5.56 and 5.63 nM, respectively) (Tables 2.2 and 2.7). Also, the potencies of GR89696 
and ICI 199,441 were very similar, based on comparison of results obtained from the Tango and 
BRET arrestin assays. U62066 has a slightly higher potency in the BRET assay compared with 
the Tango assay (19.8 and 6.21 nM, respectively). This shift in potency has a modest effect on 
the bias factor calculated with the BRET data as compared with the Tango data, but both assays 
suggest a slight G protein bias for U62066 (Table 2.8). Furthermore, RB 64, RB 48, RB 59, RB 
55, Dyn 1–13, Dyn 1–9, Dyn 1–11, and Dyn A all have slightly higher potencies in the BRET 
arrestin assay than the Tango assay, while Dyn 1–8 has a slightly more potent effect in Tango 
than BRET. 
 Despite modest potency differences between the Tango and BRET assays, if a ligand was 
identified as biased in the Tango assay then it was also identified as biased using the BRET 
arrestin assay. A comparison of bias factors generated from the BRET arrestin assay and the 
Tango assay is shown in Table 2.8, and the log(t/KA) values are listed in Table 2.9. 
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2.4 CONCLUSIONS 
 Recent structural evidence suggests that G protein-coupled receptors (GPCRs) adopt 
multiple conformations and that different ligands can stabilize distinct conformations leading to 
diverse signaling profiles (Kenakin, 1995; Liu et al., 2012; Nygaard et al., 2013; Vardy and 
Roth, 2013; Wacker et al., 2013). Additionally, signaling partners including arrestins (Gray et al., 
2003) and G proteins (Nygaard et al., 2013; Yan et al., 2008) can allosterically modulate agonist 
affinities and overall receptor conformations. This bidirectional modulation from both the ligand 
and the intracellular effector might affect its signaling.  
In this study we sought to identify KOR selective functionally selective ligands, as such 
ligands have been proposed to potentially function as analgesics with fewer adverse side effects 
(e.g. sedation and dependence). Our attempts to identify biased KOR agonists were aided by: (1) 
a wealth of diverse chemical matter reported to be KOR-selective; (2) assays that are both 
readily available and scalable; (3) and the availability of a KOR crystal structure (Wu et al., 
2012). The diverse KOR chemotypes and structural information will be useful as we attempt to 
further optimize this structurally diverse catalogue of biased ligands. Additionally, there is 
increased interest in developing KOR antagonists for both depression and addiction disorders, 
and for developing KOR agonists as analgesics with a low abuse potential (Prevatt-Smith et al., 
2011; Tao et al., 2008; Wee and Koob, 2010). However, KOR agonists also cause aversion, 
hallucinations, and psychotomimetic effects (Pfeiffer et al., 1986). To develop KOR agonists that 
can be used as analgesics, we must understand how KOR mediates these negative side effects, 
and explore the use of functionally selective ligands towards KOR therapies with minimal side 
effects. Additionally, understanding which KOR-dependent signaling cascades mediate 
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hallucinations will provide insight into how KOR activation affects cognition. Therefore, the first 
step in understanding the diverse KOR behavioral effects is to identify a range of functionally 
selective ligands that are potent and selective for KOR. In this study, we identify multiple 
centrally active KOR-selective biased ligands (RB 64, RB 48, ICI 199,441, and GR89696) that 
have the potential for probing KOR signaling pathways in vivo (Fig 2.2C) (Ravert et al., 2002; 
Terner et al., 2005; Yan et al., 2008). Fig. 2.3 is a plot of relative efficacy vs log bias of each 
ligand tested to show full the range of signaling effects identified and ideally one would test a 
ligand from each quadrant in vivo.  
Significantly, an unbiased screen of small library of known drugs yielded only a single 
KOR biased ligand (GR89696), although it is possible that larger screens encompassing greater 
chemical diversity could yield additional scaffolds. Intriguingly, when we focused our 
investigation on analogues of known KOR ligands, we were able to rapidly identify additional 
KOR ligands with varying degrees of bias. This suggests that screening scaffold derivatives is a 
reliable approach for identifying biased ligands, and mirrors our results reported for D2 arrestin-
biased drug discovery (Allen et al., 2011). After identifying a scaffold from the NCC screen, for 
instance, we tested compounds that were similar in structure to the initial arylacetamide hit. 
Additionally, we performed a similarity search using the ZINC database and found an additional 
biased ligand possessing the arylacetamide scaffold (ICI 204,448). We found arylacetamide 
ligands to be either weakly G protein or arrestin biased.  
We also tested varying lengths of the endogenous KOR peptide ligand, dynorphin, and 
found them all to be G protein biased. Additionally, we tested the RB family of salvinorin 
derivatives that were originally synthesized to covalently bind to KOR.  Future studies will be 
25 
 
needed to investigate how those ligands interact with the receptor and potentially identify 
residues mediating the signaling bias observed. The RB family of compounds constitute the first 
identified KOR G protein biased ligands that are centrally active and can therefore be used for in 
vivo probing of KOR mediated G protein signaling (Yan et al., 2009).  
 To further investigate our biased ligands, we tested arrestin recruitment in an orthologous 
assay using bioluminescence resonance energy transfer (BRET). In general, ligands tested in the 
BRET assay displayed similar potencies and efficacies when compared with results obtained 
with the Tango assay. RB 48 and RB 59, by contrast, possess the largest differences in bias 
factors quantified using Tango vs. BRET assays. Notably, the incubation time is much longer for 
the Tango assay (16hrs) and proteolysis of the transcription factor, entry into the nucleus, 
transcription and translation are required downstream of arrestin recruitment whereas only 
arrestin recruitment is assayed in the BRET assay (5 min). However, all ligands that we 
originally found to be biased using the Tango assay were also found to be biased using the BRET 
assay. Thus, we can infer that these compounds are functionally selective ligands for KOR –at 
least in HEK cells.  
 This is the first report of KOR-selective biased ligands that may ultimately be useful in 
vivo to discover which KOR signaling cascades are responsible for various KOR-mediated 
behavioral effects. Although 6′-GNTI was previously identified as a biased ligand, it has a fixed 
charge and therefore does not readily cross the blood-brain barrier (Rives et al., 2012). 
Additionally, while the log(τ/KA) method of quantifying bias is useful for calculating the bias in 
vitro, further studies are necessary for investigating the in vivo effect of these ligands, as 
efficacies and potencies in vitro may not correlate with those obtained in other cell types in vivo.  
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Nonetheless, using a similar strategy, we have been able to successfully advance arrestin-biased 
D2 agonists to in vivo testing and demonstrate that they retain substantial apparent bias in vivo 
(Allen et al., 2011; Chen et al., 2012).  
Finally, the phenomenon of GPCR functional selectivity is not limited to arrestin 
mobilization and G protein activation.  For example, we have identified 5-HT2A inverse agonists 
which can induce receptor internalization and down-regulation in vitro and in vivo without 
activating either G protein signaling or arrestin translocation (Bhatnagar et al., 2001; Xia et al., 
2003; Yadav et al., 2011). In future studies, it will be useful to combine in vivo behavioral 
studies and a global study of intracellular signaling with functionally selective ligands, in order 
to fully understand which signaling cascades contribute to the various behavioral effects of KOR 
agonism. The present study suggests that simply screening available scaffolds represents a facile 
method for identifying functionally selective ligands with good drug-like properties. The rapid 
increase in GPCR structural and dynamic information, and our expanded understanding of 
functional selectivity, has enhanced the potential for designing more selective therapies with 
fewer side effects for a multitude of diseases and conditions. In the future, screening compounds 
for a more global activation of pathways in addition to those activated by G proteins should 
allow for a better understanding of how these ligands affect physiology, and how functionally 
selective compounds might have beneficial therapeutic value.  
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 Table 2.1: Concentration response curves of compounds identified as “actives”  
from the NCC library screen 
 
Compound G protein EC50 Emax Arrestin EC50 Emax 
GR8969 0.515nM 
(-9.29 +/-0.11) 
95.38 0.25nM  
(-9.60+/-0.06) 
93.92 
Bestatin - - - - 
2-(2-aminoethyl) 
pyridine 
1050nM 
(-5.98+/-0.68) 
184 550nM 
(-6.26+/-0.09) 
110 
Guanidine, N-cyano-N’-
(1,1-dimethylpropyl)-N’’-
3-pyridinyl 
159nM 
(-6.81+/-0.34) 
85.0 233nM 
(-6.63+/-0.32) 
73 
Doxapram - - - - 
Brucine - - - - 
Diphenyoxylate - - - - 
  
 GR89696 was identified as a potent agonist for KOR for both G protein activation and 
arrestin mobilization. However, GR89696 is more potent in activating arrestin than G protein 
relative to sal A. This compound was the only potent functionally selective ligand identified in 
the NCC library. Brucine, Doxapram, and Diphenoxylate show some activity at higher doses 
(1uM and higher) but do not generate a reliable dose response curve. 
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Table 2.2: Affinity and potency values for arylacetamides using GloSensor and Tango 
Arylacetamides G protein EC50 G 
protein 
Emax 
Arrestin EC50 Arrestin 
Emax 
Bias 
Factor 
Salvinorin A 5.183 nM 
(-8.29 +/-0.10) 
99.7 5.75 nM 
(-8.24+/-0.06) 
97.2 1 
 
ICI 199,441 1.63 nM  
(-8.79 +/-0.07) 
101 0.428 nM  
(-9.37+/- 0.05) 
84.8 4 
Arrestin 
ICI 204,448 4.22 nM 
(-8.38 +/-0.09) 
111 3.28nM 
(-8.48+/-0.06) 
77.4 2 
Arrestin 
U69593 5.89 nM 
(-8.23 +/-0.07) 
109 6.42 nM 
(-8.19 +/-0.09) 
89.3 1 
GR89696 0.970 nM 
(-9.01 +/-0.11) 
96.4 0.259 nM  
(-9.60+/-0.06) 
92.8 5 
Arrestin 
U62066 1.01 nM 
(-9.00 +/-0.05) 
103 6.21 nM 
(-8.21 +/-0.10) 
92.7 6 
G protein 
(+) U50,488 246 nM 
(-6.61 +/-0.12) 
102 959 nM 
(-6.02 +/-0.08) 
92.3 8 
G protein 
(-) U50,488 0.858 nM 
(-9.06+/-0.07) 
95.5 0.822nM 
(-9.09+/-0.09) 
94.6 2 
Arrestin 
DIPPA 14.5 nM  
(-7.84+/-0.09) 
111 8.49 nM  
(-8.07 +/-0.07) 
68.5 1 
N-MPPP  4.45 nM 
(-8.35 +/-0.09) 
109 2.41 nM 
(-8.62 +/-0.06) 
79.7 1 
BRL 52537 1.85 nM 
(-8.73 +/-0.07) 
112 1.35 nM 
(-8.87 +/-0.05) 
88.9 1 
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Table 2.3: Affinity and potency values for dynorphin peptides using GloSensor 
and Tango assays 
 
Peptides 
 
G protein EC50 G protein 
Emax 
Arrestin EC50 Arrestin 
Emax 
Bias 
Factor 
Salvinorin A 5.183 nM 
(-8.29 +/-0.10) 
99.7 5.75 nM 
(-8.24 +/-0.06) 
97.24 1 
 
Dynorphin A 8.12 nM 
(-8.09 +/-0.07) 
101 268 nM 
(-6.57 +/-0.11) 
74.8 34 
G protein 
Dyn 1-8 57.7 nM 
(-7.24 +/-0.05) 
106 720 nM 
(-6.14+/-0.11) 
89.9 4 
G protein 
Dyn 1-9 10.2nM  
(-7.99+/-0.06) 
101 600nM  
(-6.22+/-0.09) 
64.7 16 
G protein 
Dyn 1-11 3.26nM  
(-8.49+/-0.08) 
101 450nM  
(-6.35 +/-0.09) 
75.8 44 
G protein 
Dyn 1-13 2.07nM  
(-8.68+/-0.07) 
96.6 97.8nM  
(-7.01 +/-0.07) 
72.4 34 
G protein 
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Table 2.4: Affinity and potency values for morphinans using GloSensor and Tango assays 
 
Morphinans 
 
G protein EC50 G protein 
Emax 
Arrestin EC50 Arrestin 
Emax 
Bias Factor 
Salvinorin A 5.18 nM 
(-8.29 +/-0.10) 
99.7 5.75 nM 
(-8.24 +/-0.06) 
97.2 1 
 
β-NNTA 0.305 nM 
(-9.52+/-0.12) 
97.0 0.268 nM 
(-9.57+/-0.12) 
84.5 1 
 
6' GNTI 4.74 nM 
(-8.32 +/-0.09) 
96.5 7.38 nM 
(-8.13 +/-0.12) 
34.7 6 
G protein 
5' GNTI Antagonist - Antagonist -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
Table 2.5: Affinity and potency values for benzomorphans using  
GloSensor and Tango assays 
 
Benzomorphans 
 
G protein EC50 G protein 
Emax 
Arrestin EC50 Arrestin 
Emax 
Bias Factor 
Salvinorin A 3.63nM  
(-8.29 +/- 0.10) 
103 6.67nM  
(-8.18+/-0.05) 
99.42 1 
 
Naltrindole Antagonist - Antagonist -  
Diprenorphine 0.960 nM 
(-9.02 +/-0.08) 
88.3 3.35 nM 
(-8.48 +/-0.14) 
87.0 2  
G protein 
Nalbuphine 61.5 nM 
(-7.21 +/-0.11) 
81.3 47.2 nM 
(-7.33+/-0.08) 
74.1 3 
Arrestin 
Butorphanol 1.82 nM 
(-8.74 +/-0.07) 
94.3 1.70nM 
(-8.77+/-0.06) 
59.2 2  
G protein 
Cyclazocine 1.19 nM 
(-8.92 +/-0.09) 
102 0.806nM 
(-9.09+/-0.03) 
81.7 1 
JDTic Antagonist - Antagonist -  
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
Table 2.6: Affinity and potency values for RB family of salvinorin derivatives using 
GloSensor and Tango assays 
 
RB 
Salvinorins 
G protein EC50 G protein 
Emax 
Arrestin EC50 Arrestin 
Emax 
Bias Factor 
G protein 
Salvinorin A 5.183 nM 
(-8.29 +/-0.10) 
99.7 5.75 nM 
(-8.24+/-0.06) 
97.2 1 
 
Salvinorin B 73.4 nM 
(-7.13 +/-0.08) 
95.9 428 nM 
(-6.37+/-0.07) 
115 4 
G protein 
RB-64 5.29 nM  
(-8.27 +/-0.06) 
101 391 nM 
(-6.41 +/-0.05) 
104 35 
G protein 
RB-48 8.82 nM 
(-8.05+/- 0.07) 
101 143 nM 
(-6.84 +/-0.09) 
63.2 25 
G protein 
RB-55_1 119nM  
(-6.93+/- 0.07) 
101 1492 nM 
(-5.83 +/-0.15) 
52.2 22 
G protein 
RB-55_2 142 nM  
(-6.84+/- 0.10) 
105 2284 nM 
(-5.64 +/-0.09) 
56.8 33 
G protein 
RB 55 31.3 nM 
(-7.50+/-0.08) 
103 229 nM 
(-6.64 +/-0.07) 
86.9 8 
G protein 
RB 50 166 nM 
(-6.78+/- 0.10) 
103 3812 nM 
(-5.42+/-0.21) 
89.2 69 
G protein 
RB 59 35.8 nM 
(-7.45+/-0.10) 
95.7 4290 nM 
(-5.37+/-0.13) 
76.6 95 
G protein 
RB 65 145 nM 
(-6.83+/-0.10) 
95.9 2767 nM 
(-5.56+/-0.13) 
42.7 29 
G protein 
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Table 2.7. BRET arrestin affinity and potency values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound EC50 Emax 
Salvinorin A 5.55 nM  (-8.25+/-0.05) 98.84 
GR89896 0.265 nM  (-9.58+/-0.03) 104 
ICI 199,441 0.461 nM  (-9.34+/-0.07) 100 
U62066 19.8 nM  (-7.70+/-0.07) 101 
RB 64 118 nM   (-6.93+/-0.06) 105 
RB 48 45.0 nM  (-7.35+/-0.06) 101 
RB 55 196 nM   (-6.71+/-0.03) 78.9 
RB 59 3560 nM (-5.44+/-0.18) 177 
Dyn 1-13 78.2 nM  (-7.11+/-0.13) 86.3 
Dyn 1-11 132 nM   (-6.87+/-0.16) 86.9 
Dyn 1-9 253 nM   (-6.59+/-0.11) 92.8 
Dyn 1-8 1070 nM (-5.97+/-0.11) 102 
Dynorphin A 112 nM   (-6.95+/-0.13) 99.2 
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Table 2.8: Comparison of Bias Factor generated with Tango and BRET assays 
Compound EC50  and 
Emax 
GloSensor 
EC50 and 
Emax 
Tango 
EC50  and 
Emax 
BRET 
Bias Factor 
(Tango) 
Bias Factor 
(BRET) 
Salvinorin A 5.18 nM 
99.7 
5.75 nM 
97.2 
5.54 nM 
98.8 
1 1 
GR89696 0.970 nM 
96.4 
0.259 nM 
92.8 
0.265 nM 
104 
5 Arrestin 5 Arrestin 
ICI 199,441 1.63 nM 
101 
0.428 nM 
84.8 
0.461 nM 
100 
4  Arrestin 4 Arrestin 
U62066 1.01 nM 
103 
6.21 nM 
92.3 
19.8 nM 
101 
6 G protein 18 G protein 
RB 64 5.29 nM 
102 
391 nM 
103 
118 nM 
105 
35 G protein 13 G protein 
RB 48 8.82 nM 
101 
143 nM 
63.2 
45.0 nM 
101 
25 G protein 4  G protein 
RB 55 31.3 nM 
103 
229 nM 
86.9 
196 nM 
79.0 
8  G protein 10 G protein 
RB 59 35.8 nM 
95.7 
4290 nM 
76.6 
3560 nM 
177 
95 G protein 35 G protein 
Dyn 1-13 2.07 nM 
96.6 
97.8 nM 
72.4 
78.2 nM 
86.3 
34 G protein 32  G protein 
Dyn 1-11 3.26 nM 
101 
450 nM 
75.8 
253 nM 
92.0 
44 G protein 27  G protein 
Dyn 1-9 10.2 nM 
101 
600 nM 
64.6 
132 nM 
86.9 
16 G protein 15  G protein 
Dyn 1-8 57.7 nM 
106 
720 nM 
89.9 
1068 nM 
103 
4 G protein 8    G protein 
Dyn A 8.12 nM 
101 
268 nM 
74.8 
112 nM 
99.2 
34 G protein 20  G protein 
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Table 2.9: LogTau/KA values for all ligands tested 
Drug LogTau/KA 
GloSensor 
LogTau/KA Tango LogTau/KA BRET 
Salvinorin A 8.197 +/-0.08 8.175 +/-0.07 8.182 +/-0.04 
U69593 8.140 +/-0.08 8.126 +/-0.06  
(+) U50488 6.783 +/-0.09 5.873 +/-0.09  
U62066 8.979 +/-0.09 8.173 +/-0.08 7.563 +/-0.11 
DIPPA 7.838 +/-0.09 7.765 +/-0.09  
N-MPPP 8.621 +/-0.09 8.423 +/-0.08  
BRL 52537 8.843 +/-0.09 8.702 +/-0.07  
ICI 204488 8.025 +/-0.08 8.255 +/-0.12  
ICI 199441 8.587 +/-0.07 9.189 +/-0.05 9.188 +/-0.05 
GR8969 8.819 +/-0.08 9.492 +/-0.06 9.506 +/-0.05 
(-)U50488 8.600 +/-0.09 8.910 +/-0.09  
Beta-NNTA 9.395 +/-0.13 9.354 +/-0.09  
6' GNTI 8.252 +/-0.08 7.489 +/-0.23  
Diprenorphine 8.615 +/-0.11 8.404 +/-0.10  
Butorphanol 8.611 +/-0.09 8.249 +/-0.19  
Nalbuphine 6.735 +/-0.14 7.240 +/-0.16  
Cyclazocine 8.771 +/-0.09 8.804 +/-0.14  
RB 48 7.87 +/-0.07 6.44 +/-0.09 7.221 +/-0.06 
RB 64 7.94 +/-0.07 6.38+/-0.06 6.824 +/-0.06 
RB 50 6.89 +/-0.12 5.03 +/-0.13  
RB 65 6.56 +/-0.13 5.08 +/-0.22  
RB 59 6.98 +/-0.10 4.97 +/-0.12 5.400 +/-0.70 
RB 55-2 6.74 +/-0.08 5.19 +/-0.15  
RB 55-1 6.85 +/-0.09 5.49 +/-0.15  
RB 55 7.32 +/-0.09 6.42 +/-0.07 6.286 +/-0.14 
Salvinorin B 6.89 +/-0.10 6.30 +/-0.05  
Dyn 1-13 8.497 +/-0.04 6.94 +/-0.09 6.979 +/-0.16 
Dyn 1-9 7.636 +/-0.07 6.415 +/-0.13 6.439 +/-0.12 
Dyn 1-11 8.263 +/-0.07 6.594 +/-0.12 6.816 +/-0.22 
Dyn 1-8 7.249 +/-0.07 6.574 +/-0.09 6.344 +/-0.14 
Dyn A 8.149 +/-0.06 6.590 +/-0.12 6.825 +/-0.09 
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Figure 2.1: Depiction of the parallel screening approach and results of the NCC 
library screen 
 
A.) Depiction of the parallel screening approach used. B.) Scatter plot showing the results of the 
screening of the NCC library in the arrestin assay. 1: Bestatin; 2:GR8969; 3: 2-(2-aminoethyl) 
pyridine; 4: N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridinylguanidine; 5: Brucine; 6: 
Doxapram; 7: Diphenoxylate. 
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Figure 2.2: Arrestin mobilization and G protein activation dose-response curves of 
candidates for future studies. 
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Figure 2.3: Log Relative Max vs Log Bias of tested compounds 
 This figure summarizes the functional effects of the ligands tested.   The best approach 
for testing biased compounds in vivo is to test a compounds from each quadrant because the 
ligands in each quadrant are biased via different signaling effects.   The cell type specific 
signaling effect cannot be predicted so testing compounds that cause a variety of biased effects 
would be ideal. 
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CHAPTER 3: IN VIVO PROBING OF SELECT KAPPA OPIOID RECEPTOR 
SIGNALING PATHWAYS 
3.1 INTRODUCTION AND RATIONALE 
In the past decade, the phenomenon of functional selectively has been increasingly 
explored, providing an additional opportunity for GPCR-targeted therapies with improved safety 
and fewer side effects (Urban et al., 2007). The term “functional selectivity” or “biased agonism” 
describes the ability of a ligand to selectively activate a subset of signaling cascades of a 
particular receptor, as opposed to the activation of all downstream signaling cascades (G 
proteins, arrestins, and/or kinases for example). Currently, the field is investigating the potential 
for biased agonist therapies for a wide range of targets and disease states: for example, the 
angiotensin II receptor (acute heart failure), the μ-opioid receptor (postoperative pain and 
moderate to severe pain), the δ-opioid receptor (Parkinson’s disease, pain, and depression), and 
the dopamine D2 receptor (schizophrenia and related disorders). (Allen et al., 2011; DeWire et 
al., 2013; Monasky et al., 2013; Pradhan et al., 2011; Whalen et al., 2011) Additionally, recent 
studies have suggested a potential for biased KOR ligands as analgesics with lower addiction 
potential and fewer side effects (Bruchas et al., 2007a; Ranganathan et al., 2012; Tao et al., 
2008).  
Kappa opioid receptor (KOR) agonists have therapeutic potential because they induce 
analgesia-like effects with a low potential for drug abuse. However, KOR agonists cause many 
negative side effects such as dysphoria, anhedonia, and hallucinations (Tejeda et al., 2013; 
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Pfeiffer et al., 1986; Ranganathan et al., 2012). Stimulation of KOR leads to KOR-dependent 
p38 MAPK activation in vivo, and this p38 activation mediates KOR-induced aversion in mice, 
but not analgesia (Bruchas et al., 2007a). This activation of p38 has been hypothesized to be 
mediated by β-arrestin 2 signaling (Bruchas and Chavkin, 2010), suggesting a therapeutic 
potential for G protein-biased KOR ligands to produce analgesia free of dysphoria. However, 
this hypothesis has not been directly tested by examining either β-arrestin 2 KO mice or KOR-
selective biased ligands to probe individual KOR signaling pathways in vivo.  
To better understand which KOR signaling pathways mediate specific behavioral outputs, 
we first examined WT and β-arrestin 2 KO mice treated with unbiased KOR agonists to measure 
well- established KOR-mediated effects, such as analgesia, aversion, deficits in motor 
coordination, sedation, and anhedonia-like effects. The absence of a normal KOR behavior in β-
arrestin 2 KO mice would suggest that β-arrestin 2 signaling might mediate that behavior. As an 
orthologous approach, we tested a G protein-biased, KOR-selective ligand (RB 64) in these 
behavioral paradigms, along with the KOR-selective unbiased ligands U69593 and sal A ((White 
et al., 2014); Chapter 2).  
Using this approach, we determined that KOR-promoted G protein signaling induces 
analgesic-like effects and aversion, while KOR-promoted β-arrestin 2 signaling induces motor 
incoordination. Additionally, the G protein-biased ligand RB 64 had no effect on motor 
coordination, sedation, or anhedonia, suggesting that these behaviors are not mediated by G 
protein signaling but perhaps by β-arrestin 2 signaling. Based on these results, there is potential 
for developing G protein-biased KOR therapies for inducing analgesia with reduced abuse 
potential and fewer deleterious side effects.  
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3.2  METHODS 
In Vitro functional analysis of U69593, sal A and RB 64  
G protein activation assay was measured by the GloSensor assay (Promega) and arrestin 
mobilization was measured by Tango assay exactly as described in Chapter 2 except the mouse 
KOR was used instead of human KOR. Additionally, bias calculations were performed exactly 
as described in Chapter 2. 
 
Animal Subjects 
C57BL/6 mice and KOR KO mice were acquired from The Jackson Laboratory (Bar 
Harbor, ME), and β-arrestin 2 KO mice were donated by the laboratory of Robert Lefkowitz 
(Duke University, Durham, NC). Behavioral studies were conducted at the University of North 
Carolina following the National Institute of Health’s guidelines for care and use of animals and 
with approved mouse protocols from the Institutional Animal Care and Use Committees. 
Subjects were age matched, 2- to 8-month-old mice weighing between 22 and 35 g; genotypes 
were determined by PCR analysis of tail tip digestions. WT and β-arrestin 2 KO mice from β-
arrestin 2 KO heterozygous parents (C57BL/6 background) were used for all behavioral 
experiments.  All mice were given food and water ad libitum. 
 
Drugs 
Salvinorin A (sal A) was acquired from Apple Farms (Asheville, NC) and 22-
thiocyanatosalvinorin A (RB 64) was synthesized as previously reported (Yan et al., 2009). 
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Lastly, (+)-(5α,7α,8β)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
benzeneacetamide (U69593) was acquired from Sigma (St. Louis, MO). All drugs were 
administered subcutaneously using 10% Tween-80 as vehicle, unless otherwise stated. 
 
Hotplate Assay 
Analgesia-like responses were measured using a hotplate analgesia meter with 
dimensions of 29.2 x 26.7 cm, with mice restricted to a cylinder 8.9 cm in diameter and 15.2 cm 
high (IITC Life Sciences, Woodland Hills, CA). Response was measured by recording the 
latency to lick, flutter, or splay hind paw(s), or an attempt to jump out of the apparatus at 55 °C, 
with a maximum cutoff time of 30 s. Once a response was observed, or the cutoff time had 
elapsed, the subject was immediately removed from the hotplate and placed back in its home 
cage (Balter and Dykstra, 2013). The animals were acclimated to the hotplate, while cool, and a 
baseline analgesic response time was acquired several hours before drug treatment and testing. 
The analgesia-like effect was measured 10, 20, and 30 minutes after treatment administration. If 
animals did not display hind paw lick, splay, or flutter, they were removed from the trial.   
  
Conditioned Place Aversion 
The conditioned place aversion protocol was modified from (Medvedev et al., 2005). 
Apparatus. Drug-naïve mice were used for each treatment condition. A three-
compartment place preference chamber was used under standardized environmental conditions 
using an AccuScan activity monitor system (AccuScan Instruments, Columbus, OH). The 
location of the subject was detected by photobeam strips, and the time spent in each 
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compartment was recorded. The experiments were conducted in a room used only for animal 
behavior studies, and no other activity in the room occurred during testing. The three 
compartments of the chamber can be separated by sliding doors, and the center compartment was 
40 cm long, 30 cm deep, 5 cm wide with white walls and plastic floor. The two larger 
compartments used during training were 40 cm long, 30 cm deep, and 17.5 cm wide. One 
compartment had white and black vertical stripes with brown, perforated paper strips on the 
flooring, and the other conditioning chamber had white and black vertical stripes with Diamond 
Dry bedding (Harlan Laboratories, Indianapolis IN) on the floor.  
Pretest (Days 1-3). During this phase, mice were placed in the center compartment and 
the doors were opened, so both test chambers were accessible. The location of the mice was 
monitored for 15 minutes during three days of pretest training. Mice were not considered suitable 
for testing if they did not meet the following criteria during the pretest: they cannot spent more 
than 25% of the time in the center compartment, they cannot spend less than 25% of the time in 
one of the conditioning compartments, and/or they cannot spend more time in the center 
compartment than one of the conditioning compartments (Medvedev et al., 2005). 
Conditioning Phase (Days 4-9). Vehicle treatments were performed on days 4, 6, and 8 
and restricted to the test chamber that the particular mouse spent the least amount of time in 
during the pretest phase. Drug treatments were conducted on days 5, 7, and 9 and restricted to the 
test chamber that the particular mouse spent more time in during the pretest. The vehicle control 
mice received vehicle in both compartments during conditioning. Fifteen minutes after drug 
treatment, mice were placed in the conditioning chamber for an additional 15 minutes. 
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Test Phase (Day 11). After a one day drug washout period, mice were placed in the 
center chamber and the doors were opened to allow access to all rooms. No drug or vehicle was 
given on this day, and the location of the mouse was measured for 15 minutes. Data were pooled 
over the 15 minute testing phase for each mouse, and the CPA result was analyzed for each 
mouse. The results were recorded as the difference in time spent in the drug-paired compartment 
on the test day vs pretest day. 
 
Rotarod Performance 
 Balance and motor coordination were measured on an accelerating rotarod after drug 
treatment (Ugo-Basile, Stoelting Co., Wood Dale, IL) as previously reported (Huang et al., 
2013). Briefly, the rod initially rotated at 3 rpm, gradually increasing to a maximum of 30 rpm 
over a 5 minute period, which was also the maximum length of the trial. Two days prior to the 
experiment, mice were trained on the apparatus in 2-3 trials, with a 1 minute break between 
trials. The latency to fall off the rod was measured by the rotarod timer. Additionally, mice were 
stopped from testing if they rotated off the top of the rod. On testing days, each mouse first 
completed a drug-free trial to determine baseline performance before administration of drug. 
Rotarod performance was assessed 10, 20, and 30 minutes after drug administration.   
Novelty Induced Locomotion 
Mouse locomotion was measured in photocell-based activity chambers under 
standardized environmental conditions using an AccuScan activity monitoring system 
(AccuScan Instruments, Columbus, OH) consisting of a 41x41x30 cm chamber and beam 
sensors as described (Farrell et al., 2013). Distance traveled consists of horizontal movement 
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throughout the entire chamber, and data were collected in 5 minute bins. Mice were given drug 
or vehicle treatments 15 minutes prior to being placed in the chamber and locomotion was 
recorded for 1 hour.   
 
Intracranial Self-Stimulation (ICSS) 
ICSS is an operant behavioral method in which mice respond for rewarding electrical 
stimulation of the medial forebrain bundle at the level of the lateral hypothalamus. All ICSS 
methods were done as previously described (Robinson et al., 2012), using a curve-shift method 
of ICSS (Carlezon and Chartoff, 2007).  
   
Statistics 
The data are presented as means and standard errors of the mean (SEM). The hotplate, 
CPA, rotarod, and novelty induced locomotion studies were analyzed by Graphpad Prism 
statistical software (La Jolla, CA) while the ICSS studies were analyzed by SPSS statistical 
software (IBM Cor., Armonk, NY). The hotplate data were assessed with a two-way repeated 
measures (RM) ANOVA for within subject effect of time, between subject effect of treatment, 
and interaction between time and treatment. The effect of KOR on results was determined by a 
one-way ANOVA analysis of the results from KOR KO mice compared with WT mice. 
Additionally, the effect of genotype on baseline performance was measured by one-way 
ANOVA. Results are plotted as % baseline for each mouse. The CPA and novelty induced 
locomotion data were first assessed by a Bartlett’s test for equal variances to determine if the 
variances differ significantly followed by a one-way ANOVA. A two-tailed t-test was performed 
46 
 
with the drug treatments dissolved in DMSO vehicle controls to determine potential ceiling 
effects of the 10% Tween-80 vehicle on 1mg/kg U69593 and 3mg/kg RB64.  
Rotarod data were assessed by a two-way RM ANOVA for each treatment condition. The 
within subject effect of time, the between subject effect of genotype, and the effect of time on 
genotype were reported. A one-way ANOVA was used to analyze any difference between 
baseline performances for each genotype. Results are plotted as % baseline performance for each 
mouse. Novelty induced locomotion data were assessed by a two-way RM ANOVA to determine 
effect of genotype on locomotion. To determine the effect of treatment on total distance traveled 
and the effect of treatment on center time one-way ANOVAs was performed. Prior to one-way 
ANOVA analysis a Bartlett’s test for equal variances was performed. Data which did not satisfy 
this criteria were log transformed prior to one-way ANOVA analysis, which was only the case 
for the center time data. 
ICSS data were assessed by a two-way RM ANOVA to compare the effects of drug and 
dose. All BSR threshold and MAX values were represented as percentage of the pre-drug 
baseline for each mouse. The effects of treatments on average rate-frequency curves a two-way 
RM ANOVA was performed. For all data sets assessed with two-way RM ANOVA and one-way 
ANOVA, when significant (p< 0.05) all post-hoc analyses were by Bonferroni corrected pair-
wise comparisons. To satisfy assumptions for parametric analysis, one-way ANOVA, data were 
evaluated for equal variances using Bartlett’s test.  
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3.3       RESULTS 
3.3.1 RB 64 Is A G Protein-Biased Ligand At The Mouse KOR 
RB 64 was originally identified as a G protein-biased ligand from a screen using the 
human KOR (White et al., 2014). In an in vitro assay system we showed that RB 64 is also a G 
protein-biased ligand for the mouse KOR (bias factor = 79), while U69593 is unbiased (bias 
factor = 3) relative to sal A (Table 1). 
 
3.3.2 KOR-promoted G Protein Signaling Induces Analgesia-like Effects 
U69593 had analgesia-like action in both WT mice (F(1,54) = 5.73, p = 0.0277) and β-
arrestin 2 KO mice (F(1,51)  = 6.46, p = 0.0211) compared to vehicle treated mice, but there was 
no difference in analgesia-like effects between genotypes (F(1,48) = 2.05, p = 0.1719) (Fig. 3.2a). 
Additionally, the analgesia induced by U69593 in both WT showed temporal variability (F(3,54) = 
8.91, p < 0.0001) and β-arrestin 2 KO mice (F(3,51 )= 7.85, p = 0.0002). Furthermore, there was an 
interaction of time and U69593 treatment compared to vehicle treated mice in WT mice (F(3,54) = 
11.93, p < 0.0001) and β-arrestin 2 KO mice (F(3,51) = 4.25, p = 0.0093). WT mice showed an 
analgesia-like effect at 10 and 20 minutes post U69593 treatment (p < 0.001) and β-arrestin 2 
KO mice displayed an analgesia-like effect 10 minutes (p < 0.01) and 20 minutes (p < 0.05) after 
U69593 treatment.  
There was also an analgesia-like effect of 3 mg/kg sal A in WT mice (F(1,63) = 5.10, p = 
0.0347), but not β-arrestin 2 KO mice (F(1,69) = 2.08, p = 0.1626). However, there was no 
difference in analgesia-like effects between WT and β-arrestin 2 KO mice (F(1,75) = 0.03, p = 
0.8565) (Fig. 3.2b), and there was an effect of time on analgesia for both WT (F(3,63) = 4.90, p = 
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0.0040) and β-arrestin 2 KO mice (F(3,69) = 5.70, p = 0.0015). Additionally, there was an 
interaction of sal A treatment and time for both WT (F(3,63) = 3.51, p = 0.0201) and  β-arrestin 2 
KO mice (F(3,69) = 3.14, p = 0.0309). The analgesia-like effect of sal A occurred 10 minutes post 
treatment for both WT and β-arrestin 2 KO mice (p < 0.01).  
RB 64 (3 mg/kg) caused an analgesia-like effect in WT (F(1,57) = 8.53, p = 0.0088) and β-
arrestin 2 KO mice (F(1,48) = 9.25, p = 0.0078), but there was no difference in response between 
WT and  β-arrestin 2 KO mice (F(1,48) = 0.16, p = 0.6958) (Fig. 3.2c). There was also an effect of 
time on analgesia in both WT (F(3,57) = 7.92, p = 0.0002) and β-arrestin 2 KO mice (F(3,48) = 9.68, 
p = 0.0001). Furthermore, there was an interaction of time and treatment for both WT (F(3,57) = 
5.81, p = 0.0016) and β-arrestin 2 KO mice (F(3,48) = 2.96, p = 0.0417). The analgesia-like effects 
of 3 mg/kg RB 64 occurred 20 minutes after treatment (p < 0.001, WT mice; and p < 0.01, β-
arrestin 2 KO mice) and 30 minutes after treatment (p < 0.05, for both WT and β-arrestin 2 KO 
mice). 
To determine if KOR mediated the analgesia-like effects of drug treatments, KOR KO 
and WT mice were treated with 1 mg/kg U69593, 3 mg/kg sal A, or 3 mg/kg RB64 (F(5,40) = 
4.734, p = 0.0017) (Fig. 3.2d). There was an absence of analgesia-like effects in KOR KO mice 
for all treatments (p < 0.05). Furthermore, there was no effect of genotype on analgesia-like 
effects of vehicle treated mice (F(1,48) = 0.37, p = 0.5526) (Fig. 3.2a-c). However, genotype did 
affect the baseline performance (F(2,33) = 3.438, p = 0.044) (Fig. 3.2e). β-arrestin 2 KO mice have 
a higher baseline than WT mice (p < 0.05), but KOR KO mice and WT mice did not differ. 
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3.3.3 KOR-Mediated G Protein Signaling Induces Aversion 
KOR agonists cause aversion in both WT and β-arrestin 2 KO mice (F(11,78) = 3.241, p = 
0.0011) (Fig. 3.3a). In WT mice there was an aversive effect of 1 mg/kg U69593 (p < 0.05), 3 
mg/kg sal A (p < 0.01), and 3 mg/kg RB 64 (p < 0.05), but no aversive effect of 1 mg/kg sal A (p 
> 0.05) and 1 mg/kg RB 64 (p > 0.05). Similarly, in β-arrestin 2 KO mice there was an aversive 
effect of 1 mg/kg U69593 (p < 0.05), 3 mg/kg sal A (p < 0.05), and 3 mg/kg RB 64 (p < 0.05), 
but there was no aversive effect of 1 mg/kg sal A (p > 0.05) or 1 mg/kg RB 64 (p > 0.05). 
Furthermore, there was no difference in aversion effects between WT and β-arrestin 2 KO mice 
for any of the treatment conditions (vehicle, 1 mg/kg U69593, 1 mg/kg sal A, 3 mg/kg sal A, 1 
mg/kg RB 64, or 3 mg/kg RB 64). 
To address the potential ceiling effect of the 10% Tween-80 vehicle on drug treatment, 
we examined the effect of 1 mg/kg U69593 or 3 mg/kg RB 64 dissolved in DMSO, instead of 
10% Tween-80. The drugs were microinjected into WT mice using a Hamilton syringe at a 
volume of 1 ul/mg (Fig. 3.3b). There was no difference in aversion effect between U69593 and 
RB 64 (t(10) = 1.237, p > 0.2442). 
 
 
3.3.4 KOR-Mediated Arrestin Signaling Produces A Deficit In Rotarod Performance 
Unbiased KOR agonists caused a strong deficit in rotarod performance, and this effect 
was greater in WT than β-arrestin 2 KO mice (Fig. 3.4). U69593 (1 mg/kg) caused a larger 
deficit in performance in WT mice than β-arrestin 2 KO mice (F(1,88) = 15.38, p < 0.003), there 
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was an effect of time on performance (F(2,88) = 49.18, p < 0.0001), but there was no interaction of 
time and genotype (F(2,88) = 0.62, p = 0.5397) (Fig. 3.4a). Similarly, 3 mg/kg sal A caused a 
stronger deficit in performance in WT mice than β-arrestin 2 KO mice (F(1,96) = 13.69, p < 
0.0006), time did effect performance (F(2,96) = 14.06, p < 0.0001), but there was no interaction 
between time and genotype (F(2,96) = 2.27, p = 0.1090) (Fig. 3.4b). Furthermore, 3 mg/kg RB 64 
had no effect on rotarod performance (Fig 3.4C). After treatment with RB 64, there was no 
genotype effect on performance (F(1,24)=0.14, p = 0.7124), there was no effect of time on 
performance (F(2,24)=0.48, p = 0.6227), and there was no effect of time on genotype (F(2,24) = 
1.42, p = 0.2617) (Fig. 3.4c).  
To ensure the specificity of drugs, we demonstrated that KOR KO animals show no 
deficit in rotarod performance when treated with 1 mg/kg U69593 or 3 mg/kg sal A. (Fig. 3.4d). 
For both drug treatments, all KOR KO animals performed at 100% baseline for all time points 
tested. Additionally, there was no difference in baseline performance among genotypes (F(2,53) = 
0.6736, p = 0.5142) (Fig. 3.4e).  
 
3.3.5 A G Protein-Biased KOR Ligand Does Not Effect Novelty Induced Locomotion 
Unbiased KOR agonists decrease novelty induced locomotion and there were no effects 
of genotype on novelty induced locomotion for all treatment conditions (Fig. 3.5a-d). Mice 
treated with vehicle habituated to conditions within about 30 minutes, meaning they decreased 
locomotion after 30 minutes. We pooled the data for the first 30 minutes of each treatment 
condition to compare the effects of all treatments and genotypes (Fig. 3.5e), and there was a 
differential effect of treatments on locomotion (F(7,49) = 21.97, p<0.0001). In both WT and β-
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arrestin 2 KO mice 1 mg/kg U69593 caused a large decrease in distance traveled (p < 0.001, for 
both WT and β-arrestin 2 KO mice) and 3 mg/kg sal A similarly decreased distance traveled (p < 
0.001, for both WT and β-arrestin 2 KO mice), but there was no effect of 3 mg/kg RB 64 on 
distance traveled (p > 0.05, for both WT and β-arrestin 2 KO mice). Additionally, there was no 
difference in distance traveled between WT and β-arrestin 2 KO mice for any treatment 
condition.  
Furthermore, there was a differential effect of treatment on center time (F(7,45) = 7.445, p 
< 0.0001) (Fig. 3.5f). Mice treated with 1 mg/kg U69593 showed an increase in center time for 
both WT and β-arrestin 2 KO mice (p < 0.001 for both). Similarly, 3 mg/kg sal A caused an 
increase in center time in both WT and β-arrestin 2 KO mice (p < 0.01 for both). However, there 
was no effect of 3 mg/kg RB 64 in either WT or β-arrestin 2 KO mice. There was also no 
difference in genotype for all treatment conditions. 
3.3.6 A G Protein-Biased KOR Agonist Does Not Induce anhedonia-like effects 
The anhedonic-like effects of U69593, sal A, or RB 64 in C57BL/6J mice were tested by 
the curve-shift method of intracranial self-stimulation (ICSS) (Carlezon and Chartoff, 2007). The 
mice responded in a frequency-dependent manner for BSR, as shown by the average baseline 
rate-frequency curves (Fig 3.6a). At 1 mg/kg, each of the three drugs produced a rightward shift 
in the average rate-frequency curve when compared to baseline, U69593 being the most potent, 
followed by sal A and RB 64 (Figure 3.6a). There was an effect of drug treatment on response 
rate (F(3,672) = 15.08, p < 0.0001), an effect of frequency on the response rate (F(14,672) = 91.70, p < 
0.0001), and an interaction between frequency and drug treatment (F(42,672) = 12.98, p < 0.0001) 
causing a rightward shift in average rate-frequency curves. 
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After a daily baseline measurement, the effects of each drug (0.01-1.0 mg/kg) on the 
minimum frequency that maintained responding (BSR threshold, Figure 3.6b), and maximum 
operant response rate (MAX, Figure 3.6c) during four 15-minute response periods post treatment 
were measured. A significant interaction was revealed between drug and dose on BSR threshold 
during the first post-treatment period (F(8,96) = 2.439, p = 0.019), the second post-treatment period 
(F(8.96)  = 8.776, p < 0.001), the third post-treatment period (F(8,96) = 6.111, p < 0.0001), and the 
fourth post-treatment period (F(8,96) = 2.499, p = 0.016). For the first post-treatment period, 1 
mg/kg sal A and U69593 elevated BSR threshold compared to vehicle (p < 0.001 for both). For 
the second post-treatment period, 0.3 U69593, 1.0 mg/kg U69593 and 1.0 mg/kg sal A elevated 
BSR threshold compared to vehicle (p < 0.001 for each). There was a differential effect of 
treatment at 1.0 mg/kg dose: U69593 vs RB 64 (p < 0.001), U69593 vs sal A (p = 0.016), and sal 
A vs RB 64 (p < 0.001). During the third and fourth post-treatment periods, 1.0 mg/kg U69593 
significantly elevated BSR thresholds when compared to vehicle (p < 0.001). Additionally, 
U69593 differed from sal A and RB64 during the third (p < 0.001) and fourth post-treatment 
period (p = 0.005 and p = 0.01; for sal A and RB 64, respectively). All doses of RB 64 had no 
significant effect on BSR. 
A significant interaction between drug and dose on MAX was revealed at the second 
post-treatment period (F(8,96) = 14.317, p < 0.001), the third post-treatment period (F(8,96) = 
18.426, p < 0.001), and the fourth post-treatment period (F(8,96) = 7.896, p < 0.001). During the 
second post-treatment period, 0.3 mg/kg U69593, 1.0 mg/kg U69593, or 1.0 mg/kg sal A 
significantly decreased MAX compared to vehicle (p = 0.001 for each). Furthermore, the drugs 
caused differential effects at the 0.3 mg/kg dose between U69593 and sal A (p < 0.001), and 
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U69593 and RB 64 (p < 0.001), but not sal A and RB 64. Additionally, the drugs had differential 
effects at a 1 mg/kg dose between all pairs of drugs: U69593 and sal A (p < 0.001), U69593 and 
RB 64 (p < 0.001), and sal A and RB 64 (p = 0.027). During the third post-treatment period, only 
U69593 (both 0.3 and 1 mg/kg) decreased MAX when compared to vehicle, sal A, and RB 64 (p 
< 0.001 for each). During the fourth post-treatment period only 1.0 mg/kg U69593 decreased 
MAX compared to vehicle, sal A, and RB 64 (p < 0.001 for each).  
 
3.4      CONCLUSIONS 
KOR agonists may be useful as analgesics without the development of dependence or 
abuse (Prevatt-Smith et al., 2011; Tao et al., 2008; Wee and Koob, 2010); however, KOR 
agonists also cause dysphoria, psychotomimesis, hallucinations, and anhedonia-like effects 
(Ebner et al., 2010; Pfeiffer et al., 1986; Potter et al., 2011; Ranganathan et al., 2012). Previous 
studies suggested that KOR-mediated p38 MAPK signaling regulates dysphoria, and KOR-
mediated G protein signaling regulates analgesia (Bruchas et al., 2007a). Until now, the role of 
KOR-mediated β-arrestin 2 signaling has not been directly tested in vivo. To further investigate 
which KOR signaling pathways contribute to specific behaviors, we examined WT and β-arrestin 
2 KO mice in a number of behavioral paradigms with a G protein-biased ligand (RB 64) and two 
unbiased ligands (U69593 and sal A). If an expected KOR-induced response is absent in β-
arrestin 2 KO mice, then β-arrestin 2 signaling may be involved in mediating that response. 
Additionally, if RB 64 fails to induce a response similar to the unbiased ligands U69593 and sal 
A, then this would suggest that RB 64 has a biased signaling profile in vivo.  
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The analgesia-like effects of U69593 and sal A shown here are similar to previous reports 
(Ansonoff et al., 2006; Waddell and Holtzman, 1999). This study shows no statistical difference 
in analgesia-like responses between WT and β-arrestin 2 KO mice treated with KOR agonists 
(Figure 3.2A-C). However, we did observe a significant difference in baseline analgesia between 
WT and β-arrestin 2 KO mice, which is consistent with previous reports (Figure 3.2E) (Bohn et 
al., 2002). Additionally, the G protein-biased ligand (RB 64) showed a significant and long 
lasting analgesia-like effect (Figure 3.2C). This long lasting effect may be due to the lack of β-
arrestin 2 recruitment, and therefore a lack of receptor desensitization, but could also be caused 
by a pharmacokinetic effect. The short acting effect of sal A was expected because it is known 
that sal A has a very short half-life in vivo due to esterase activity (Cunningham et al., 2011). 
Importantly, the analgesia-like effect of U69593, sal A, and RB 64 was shown to be specific to 
KOR and not due to an off target effect, because there was no analgesic response in KOR KO 
treated with U69593, RB 64, or sal A (Fig. 3.2D). From these experiments, we can conclude that 
G protein signaling mediates KOR-induced analgesia-like effects, which is consistent with a 
recent report of a KOR G protein-biased ligand inducing analgesia-like effects (Zhou et al., 
2013). 
Furthermore, to determine if β-arrestin 2 signaling mediates KOR-mediated aversion, as 
previously hypothesized (Bruchas and Chavkin, 2010), we examined the effects of U69593, sal 
A, and RB 64 on WT and β-arrestin 2 KO mice in the conditioned place aversion behavioral 
paradigm. U69593 and sal A have previously been shown to induce aversion in this paradigm 
(McLaughlin et al., 2003a; Shippenberg and Herz, 1986; Sufka et al., 2014; Tejeda et al., 2013; 
Zhang et al., 2005). However, one group has found that in zebrafish low doses of sal A produced 
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a conditioned place preference, and only high doses of sal A produced aversion, although the 
cause for this difference in sal A responses is unknown (Braida et al., 2007). We found that 
U69593, sal A, and RB 64 all caused a similar degree of aversion in both WT and β-arrestin 2 
KO mice (Fig 3.3A). This suggests that G protein signaling, and not β-arrestin 2 signaling, 
mediates the aversion effect measured in this assay. It is of note that CPA is a measure of 
learning, and the avoidance observed in this assay could be caused by elevations in anxiety-like 
behavior. Further investigation is necessary to better understand how RB 64 caused this aversion 
the mice. 
To further explore how G protein and β-arrestin 2 signaling contribute to KOR-mediated 
behavioral effects, we measured the performance of WT and β-arrestin 2 KO mice in the rotarod 
assay after treatment with U69593, sal A, and RB 64. This assay measures balance and motor 
coordination. The WT mice were impaired to a larger degree than the β-arrestin 2 KO mice when 
treated with either U69593 or sal A, while RB 64 had no effect on performance in either 
genotype. This suggested that β-arrestin 2 signaling may mediate KOR-induced deficit in rotarod 
performance. Furthermore, the complete lack of effect of RB 64 in suggests that there could be 
some β-arrestin 1 compensation in the β-arrestin 2 KO mice leading to the slight deficit in 
performance observed when treated with U69593 and sal A. KOR KO mice were treated with 
U69593 and sal A and showed absolutely no impairment in performance suggesting that the 
effects of U69593 and sal A are mediated through the KOR. Taken together, these data suggest 
that β-arrestin 2 signaling contributes to KOR-induced rotarod deficit, and that RB 64 is a biased 
ligand in vivo.  
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The effect of these drugs on the rotarod assay could be due to a number of factors: 
sedation, changes in motor coordination, and/or a cognitive disruption. To better understand why 
RB 64 does not affect rotarod performance but U69593 and sal A have cause an impairment in 
performance we tested the sedative effects of these drugs in the novelty-induced locomotion 
assay. We observed a decrease in locomotion in both WT and β-arrestin 2 KO mice treated with 
U69593 or sal A, but not RB 64 (Figure 3.5A-E). Although both WT and β-arrestin 2 KO mice 
showed a strong depression in locomotion, the G protein-biased ligand does not cause this effect. 
It is possible that, in this behavioral paradigm, there is compensation for the absence of β-arrestin 
2 by β-arrestin 1.  
The KOR-dynorphin system is known to be involved in the stress response (Joris et al., 
1987; McLaughlin et al., 2003a), so we measured center time during the novelty-induced 
locomotion assay to determine if these drug treatments affect anxiety-like behaviors (Figure 
3.5f). Typically, animals that are more stressed spend less time in the center and we would 
expect KOR agonists to cause a decrease in center time. However, we found that in both WT and 
β-arrestin 2 KO mice U69593 and sal A caused an increase in center time, compared to vehicle 
and RB 64. This is likely due to the sedative action of both U69593 and sal A, causing the 
animals to remain in the center more, independently of stress. Further studies on the effects of 
KOR biased ligands on anxiety-like responses are necessary to fully understand if RB 64 causes 
stress in mice. Both WT and β-arrestin 2 KO mice experience the same degree of sedation and 
center time in the novelty-induced locomotion paradigm, but a G protein biased ligand, RB 64, 
shows no effect on locomotion or center time. In this behavioral paradigm it is likely that β-
arrestin 1 compensation in the β-arrestin 2 KO mice contributes to the sedative effects observed.  
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To further explore the specific KOR-mediated signaling cascades that mediate unwanted 
side effects, we performed ICSS experiments to understand the effect of G protein-biased ligands 
on motivation and brain reward circuits. Previous reports show a negative effect of KOR 
agonists on BSR and MAX responses, meaning that treatment with KOR agonists reduces the 
hedonic value of brain stimulation reward (Ebner et al., 2010; Negus et al., 2010). Because RB 
64 appeared biased in vivo, we treated WT mice with U69593, sal A, or RB 64. Interestingly, 
U69593 and sal A reduced an animal’s motivation for stimulation, while RB 64 lacked this 
effect. Despite a lack of effect of RB 64 on novelty-induced locomotion, the rotarod assay, and 
MAX and BSR thresholds, we conclude that RB 64 is active in the brain because of the strong 
effects observed in the hotplate and CPA paradigms. Additionally, RB 64 was previously 
reported to have potent effects on prepulse inhibition (PPI). (Yan et al., 2009) However, a full 
pharmacokinetic study is necessary to determine the relative brain levels of RB 64, sal A, and 
U69593.  
KOR agonists have been shown to decrease dopamine release in the nucleus accumbens 
(NAc), and this is hypothesized to, at least in part, be responsible for the effect of KOR agonism 
on motivation (Ebner et al., 2010). Additionally, KOR agonists have been shown to have an 
inhibitory effect on dopamine release in the striatum which was hypothesized to contribute to 
aversion and decreased locomotion (Zhang et al., 2000). Furthermore, KORs on dopamerinergic 
neurons in the ventral tegmental area (VTA) have been shown to be responsible for the KOR-
mediated aversion found in mice (Chefer et al., 2013). These studies provide a clear role of KOR 
on the dopaminergic system to mediate many of the negative side effects of KOR agonism. 
Additional studies on the effect of RB 64 on dopamine release in different brain regions may 
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provide insight into how a G protein biased ligand causes analgesia-like effects but not sedative 
or anhedonia-like effects in mice. Perhaps the aversive effect of RB 64 in the CPA was caused 
by a dopamine-independent effect. In line with this, KOR activation in the dorsal raphe has been 
shown to mediate aversion in a dopamine-independent fashion (Land et al., 2009). A potential 
lack of effect on dopamine release by RB 64 could explain why RB 64 did not cause sedation 
and did not cause a deficit in rotarod performance.  
In summary, we have determined that KOR-mediated G protein signaling induces 
analgesia-like effects and aversion, while KOR-mediated β-arrestin 2 signaling mediates motor 
incoordination. Furthermore, the G protein-biased ligand, RB 64, has no effect on sedation and 
anhedonia-like effects, suggesting that the key signaling cascade involved in these behaviors is 
not G protein signaling, but perhaps β-arrestin 2 signaling. Based on these studies, there is 
potential for developing KOR-based therapies for inducing analgesia with a reduced abuse 
potential and fewer negative side effects by exploiting G protein-biased KOR ligands.  
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Table 3.1. Potencies and Efficacies of ligands for mouse KOR in vitro 
Drug G protein Activation Arrestin Mobilization Bias Factor 
Salvinorin A  4.73 nM  
(-8.33 +/- 0.04) 
10.5 nM  
(-7.98 +/- 0.05) 
1 
U69593 3.68 nM  
(-8.43 +/- 0.04) 
25.4 nM  
(-7.59 +/- 0.03) 
3       G protein 
RB 64 5.22  nM 
(-7.92 +/- 0.05) 
1200  nM  
(-5.92 +/- 0.06) 
99     G protein 
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Figure 3.1: Schematic of in vivo screening approach 
 To determine the contributions of G protein signaling and β-arrestin 2 on KOR mediated 
behavioral effects, I examined the effects of KOR agonists on WT and β-arrestin 2 KO mice in 
various behavioral paradigms. Furthermore, I tested a biased ligand identified in Chapter 2 (RB 
64) in behavioral paradigms to determine if this compound has a biased signaling effect in vivo.   
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 Figure 3.2: KOR agonist induced G protein signaling causes analgesia-like effects in the 
hotplate assay 
 
 (A) U69593 caused an analgesia-like effect in WT (N = 8) and β-arrestin 2 KO 
mice (N = 10) 10 and 20 minutes post treatment. (B) Sal A produced analgesia-like effects in 
WT mice (N = 11) and β-arrestin 2 KO mice (N = 16) 10 minutes after treatment. (C) RB 64 
induced analgesia-like effects in WT (N = 9) and β-arrestin 2 KO mice (N = 9) 20 and 30 
minutes post treatment. The vehicle treated WT mice (N = 12) and β-arrestin 2 KO mice (N = 9) 
showed no differences in response. (D) U69593, sal A, and RB 64 showed a KOR selective 
effect when comparing KOR KO mice (N = 8, for all drug treatments) and WT mice (N = 9, 7, 
and 6, for U69593, sal A, and RB 64). Mice were tested 20 minutes post treatment for U69593 
and sal A and 10 minutes post treatment for sal A. (E) There was an increased baseline 
performance in the hotplate assay for β-arrestin 2 KO mice compared to WT mice, but no 
difference in baseline between KOR KO and WT mice (N =  12 for all genotypes) (E). Data are 
plotted as % baseline performance (A-D) or latency to respond. * indicate p value < 0.05, ** 
indicate p value < 0.01, and *** indicate p value < 0.001 relative to vehicle (A-C) or KOR KO 
mice. 
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Figure 3.3: KOR agonist induced G protein signaling causes conditioned place aversion 
 
(A.) 1 mg/kg U69593 induced aversion in WT (N = 8) and β-arrestin 2 KO mice (N = 7). 
1 mg/kg sal A had no effect on WT (N = 6) or β-arrestin 2 KO mice (N = 8), but 3 mg/kg sal A 
did cause aversion in WT (N = 9) and β-arrestin 2 KO mice (N = 6). 1 mg/kg RB 64 did not 
cause aversion in WT (N = 8) or β-arrestin 2 KO mice (N = 7), but 3 mg/kg RB 64 did induce 
aversion in both WT (N = 8) and β-arrestin 2 KO mice (N = 7). All p values were generated in 
comparison to vehicle treated WT (N = 8) or β-arrestin 2 KO mice (N = 8). (B.) Using a DMSO 
vehicle instead of 10% Tween-80 did not cause an increased aversion in U69593 treated mice 
relative to RB 64. This was done to determine if 10% Tween-80 causes a ceiling effect in 
U69593 mice. This shows that with either vehicle (DMSO or 10% Tween-80) there is no 
difference in the aversion induced by U69593 and 3 mg/kg RB64. Data are plotted as amount of 
time spent in drug-paired room during post-test compared to pre-test. * indicates p < 0.05 and ** 
indicates p < 0.01. 
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Figure 3.4: β-arrestin 2 signaling contributes to KOR agonist induced rotarod deficit 
 (A.) U69593 induced a rotarod deficit in both WT (N = 23) β-arrestin 2 KO mice (N = 
23). The effect U69593 lasted for the amount of time for both genotypes, but there was a 
stronger deficit in performance for WT mice compared to β-arrestin 2 KO mice (p < 0.0003). 
(B.) Sal A also caused a deficit in rotarod performance in both WT (N = 25) and β-arrestin 2 KO 
mice (N = 25), but there was a significant effect of genotype of performance (p < 0.0006). (C.) 3 
mg/kg RB 64 had no effect on performance in either WT or β-arrestin 2 KO mice. (D.) U69593 
(N = 5) and sal A (N = 5) had no effect on rotarod performance in KOR KO mice. (E.) There is 
no difference between rotarod baseline performances between genotypes. Data are plotted as % 
baseline performance (A-D) or time spent on rod (E). 
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Figure 3.5: Effect of KOR agonists on novelty induced locomotion 
(A) The novelty-induced locomotion for vehicle treated WT (N = 7) and β-arrestin 2 KO mice 
(N = 8). Both genotypes habituated, decreased activity, after approximately 30 minutes. (B) 
U69593 did not differentially effect WT (N = 6) and β-arrestin 2 KO mice (N = 8). (C.) There 
was no difference in locomotion for sal A treatment between WT (N = 6) and β-arrestin 2 KO 
mice (N = 6). (D.) RB 64 induced similar effects in both WT (N = 6) and β-arrestin 2 KO mice 
(N = 7). (E) The total distance traveled in the first 30 minutes (time before habituation). U69593 
and sal A caused a strong decrease in activity, while RB 64 had no effect relative to vehicle 
treated mice. (D). U69593 and RB 64 increased center time relative to vehicle, but not RB 64. * 
indicates p value < 0.05 and *** indicates p value < 0.001. 
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Figure 3.6: KOR agonist induced G protein signaling mediates response in intracranial 
self-stimulation 
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 (A) The response for different frequencies of brain stimulation reward by C57BL/6J mice 
treated with 1 mg/kg drug. All treatments showed a rightward shift in the average rate-frequency 
curves compared to vehicle; where U69593 had the largest effect, followed by sal A, and then 
RB 64 (N = 13 for all conditions). (B) Dose-response relationship for the effects of U69593, sal 
A, and RB 64 on the brain stimulation reward threshold (BSR). Results are presented as mean 
percentages of pre-injection baseline during the four 15 minute post-injection response series +/- 
SEM. * indicate significance (p < 0.05) of drug vs. vehicle and # indicate significance (p < 0.05) 
of drug compared to another drug treatment. (C) Dose-response relationship for the effects of 
U69593, sal A, and RB 64 on the maximum response rate (MAX) in C57BL/6J mice. Results are 
presented as mean percentage of pre-injection baseline during the four 15 minute post-injection 
response periods +/- SEM. * indicate significance (p < 0.05) vs vehicle and # indicate 
significance (p < 0.05) vs a separate drug treatment. 
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CHAPTER 4: FUTURE DIRECTIONS 
4.1 INTRODUCTION 
My dissertation research focused on investigating the potential of biased-KOR ligands for 
therapeutic uses. I demonstrated the ability to screen known KOR-selective scaffold derivatives 
to identify functionally selective ligands for KOR, and this approach might be applicable for 
other GPCRs. I showed that KOR-selective G protein-biased ligands might have potential roles 
as analgesics with fewer negative side-effects than traditional narcotics, but further investigation 
is needed to better understand the cognitive and stress effects of G protein-biased KOR ligands.   
 
4.2 DETERMINING THE MOLECULAR BASIS FOR KOR FUNCTIONAL 
SELECTIVITY  
Because the structure of KOR has been solved and we were able to identify multiple 
biased-KOR ligands with unique chemical scaffolds, we can begin to investigate the structure 
activity relationship that produces biased signaling. The KOR structure was solved in the 
inactive conformation bound to JDTic, but mutagenesis and modeling studies have provided 
insight into which residues are responsible for binding and activation (Vardy et al., 2013; Wu et 
al., 2012; Yan et al., 2009). Extending these studies to compare how specific residues within the 
orthosteric binding site affect G protein signaling vs. arrestin mobilization might identify key 
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residues that modulate functional selectivity. Small ligand-induced conformational changes in 
the binding pocket are translated to larger cytoplasmic conformational changes by receptor 
“microswitches” (Wacker et al., 2013). Once these “biasing” residues have been identified, we 
might be able to rationally design ligands with improved functional selectivity for future in vivo 
studies. 
Previous studies suggest that under the appropriate conditions, RB 64 covalently binds KOR 
at the C315 position (Yan et al., 2009). C315 was not identified as a key residue involved in binding 
sal A (Wu et al., 2012; Yan et al., 2009), indicating that the RB 64 interaction with C315 might be 
partially responsible for conformational changes that mediate G protein-biased signaling. I examined 
the role of the C315A mutant in G protein activation and β-arrestin 2 mobilization to determine if 
this mutant could force sal A into a biased signaling state relative to the WT KOR-sal A 
response. Stimulation of C315A-KOR with sal A induces G protein signaling similar to WT-
KOR, but β-arrestin 2 mobilization was induced with reduced potency compared with WT-KOR 
(Fig. 4.1; Table 1.4) In this case, the drug does not induce the functional selectivity, but the 
mutation alters the receptor signaling. 
In the crystal structure of KOR, C315 does not point into the orthosteric binding site but 
instead points into the interphase between helix VI and helix VII (Fig 4.2). Conformational changes 
in helix VI have been implicated in G protein activation, and rearrangements in the intracellular 
region of helix VII have been implicated in arrestin signaling (Liu et al., 2012; Rasmussen et al., 
2011; Wacker et al., 2013). The C315A mutation might disrupt the interphase between helix VI and 
helix VII, inhibiting the full conformational changes in helix VII that lead to arrestin mobilization. 
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The effects of the C315A point mutation suggest that specific ligand-residue interactions could 
facilitate functional selectivity. 
 Further mutagenesis and modeling are necessary to fully understand the ligand-residue 
interactions in the binding pocket of KOR that mediate RB 64 functional selectivity. Mutations 
resulting in minimal changes in the binding affinity and receptor expression are ideal for further 
investigation. A thorough analysis of the relationship between single point mutations on ligand 
binding and G protein signaling has been provided (Vardy et al., 2013). Mutations in Y139, 
M142, K227, H291, and Y320 had negative effects on G protein signaling by a mechanism other 
than the binding affinity. One or more of these mutations might induce potent activation of 
arrestin mobilization and weak G protein signaling upon stimulation, which would indicate that 
those mutations would have an arrestin biasing effect. Additionally, residues that had an equal 
effect on binding and G protein activation are of interest because these mutations might affect 
arrestin mobilization and might not affect G protein signaling, which could lead to a G protein 
biased effect. Residues with this type of effect are Q115A, Y119A, M226A, I294A, E297A, and 
Y312A. The location of the residues in question are shown in Fig. 4.2.  
Ongoing efforts are underway to determine the ligand-induced conformational changes 
that mediate functional selectivity using site-specific 
19
F NMR labels in KOR. This approach 
was successful in observing ligand-induced rearrangements in helix VI and VII for multiple 
ligands bound to the β2-AR (Liu et al., 2012). 
13C NMR was also used with the β2-AR to further 
understand the ligand-induced receptor rearrangements that mediate specific signaling patterns 
(Nygaard et al., 2013). These studies showed that biased ligands differentially affect the 
microswitches involved in GPCR activation, but further knowledge of which residues within the 
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binding pocket mediate these effects is necessary to fully understand how these residues mediate 
functional selectivity. Also, increased understanding of how functionally selective ligands induce 
conformational changes in the micro-switches of multiple receptors will further our 
understanding of GPCR activation. This will be useful for drug design and for designing tools for 
the in vivo probing of select signal transduction pathways in specific brain regions.  
 
4.3 COMPLICATIONS OF CELL TYPE SPECIFIC EFFECTS 
A major complication in investigating functionally selective ligands in vivo is that 
different cell types have different effects on the overall signaling observed because of unique 
expression patterns. Many of the possible causes and effects of cell type specific signaling are 
discussed here.  
A diversity of cell types exist within the brain with different protein expression patterns 
that are unique for their specific purposes. One can hypothesize that the downstream signaling of 
KOR is different in certain populations of neurons. For example, a certain cell type might have 
altered expression of G proteins, which could affect downstream signaling in two ways: the 
receptor might preferentially couple to a different G protein, and coupling with different G 
proteins could affect the receptor conformation, altering the interactions with agonists (Yan et 
al., 2008). Additionally, the membrane lipid content of cells can affect agonist binding and might 
produce different downstream signaling effects (Lagane et al., 2000; Zocher et al., 2012). There 
might also be unknown interacting proteins that have unique expression patterns in different cell 
types that could alter downstream signaling, and this could make interpreting the results of drug 
treatments more complicated.  
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It is conceivable that certain cell types might have unique mechanics and/or different 
kinetics of receptor internalization and degradation that could affect the overall signaling output. 
Different cell types have unique mechanisms for receptor desensitization and resensitization 
(Gray et al., 2001). Additionally, a recent study demonstrated endosomal signaling of GPCRs, 
and this phenomenon might be uniquely regulated in different cell types (Irannejad et al., 2013). 
Finally, there are many reports of ligands differentially interacting with heterodimers (Yekkirala 
et al., 2011). While this concept remains controversial, it is possible that different cell types 
might allow for differing combinations of dimers that might present unique signaling outcomes. 
In any of these potential scenarios, a ligand might have different signaling effects in different 
regions of the brain. 
These different effects could potentially complicate the interpretation of results, so 
having a method to confirm signaling patterns in vivo would have a huge impact on the field. To 
accomplish this, a tool for reporting signaling that could convert a specific transient receptor 
signaling state into a stable readout via a reporter gene expression must be developed.  
4.4 DEVELOPING METHODS FOR DETECTING SPECIFIC SIGNALING 
PATHWAYS IN VIVO 
The in vivo mapping of receptor activation was previously used to detect endogenous 
modulators of feeding behavior and identify the circuits that these receptors mediate in 
drosophila (Inagaki et al., 2012). The TANGO-map method was used for this study; this method 
is based on the Tango technology described in Chapter 2. This technology was used to map 
dopamine D2 receptor activation throughout the drosophila brain. This type of technology could 
be applied to examine different signaling cascades activated by biased ligands throughout the 
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brain. There is a major focus in the field of neuroscience to map neural circuits, and mapping the 
biased signaling effect of a functionally selective ligand is a logical step. It would be ideal to 
have a genetically encoded reporter system that produced one output for G protein signaling and 
a second output for arrestin signaling to allow for the detection of differences in the biased 
signaling effects in different neuronal subtypes.  
 Another approach to detect multiple transient signals within the same cell would be to use 
a genetic logic gate. A logic gate is a device that performs a logical operation on one or more 
inputs and produces a single output, and logic gates were first implemented using transistors as 
electrical switches. The use of Boolean logic is extending to molecules and cell signaling with an 
end goal of studying signaling systems in vivo. This type of approach has been used to determine 
if two transient cellular signals occur simultaneously in the same cell (Bonnet et al., 2013; 
Stanton et al., 2014; Wang et al., 2011). This technology might also be used to detect if a 
particular ligand causes a biased signaling effect in a subset of brain regions as opposed to a 
uniform signaling effect in all brain regions and cell types. Developing this type of technology is 
challenging but would provide major insights into the possible cell type specific effects of 
different ligands. 
 
4.5 DEVELOPING TOOLS FOR ACTIVATING SELECT SIGNALING PATHWAYS 
IN VIVO 
In addition to using biased ligands to study the effects of specific signaling cascades in 
vivo, we could also develop orthologous approaches to induce a certain signaling output within a 
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specific brain region. This type of approach will be useful when functionally selective ligands 
are unavailable and will be useful in determining how a certain signaling cascade affects 
behavior through action in a specific brain region. As mentioned in Chapter 1, this approach has 
been used with a rat KOR containing a point mutation in the C-terminal tail preventing 
phosphorylation by GRK3 and subsequently preventing p38 MAPK activation (Bruchas et al., 
2007a). This approach relied on using KOR KO mice and viral delivery of the synthetic rat KOR 
receptor. An improvement in this approach would be to develop a biased KOR DREADD 
(designer receptor exclusively activated by a designer drug) because WT mice could be used 
instead of KOR KO mice. At this time, no β-arrestin 2 biased ligands have been identified that 
are suitable for in vivo study, so designing a β-arrestin 2 biased KOR DREADD would be 
extremely useful in further understanding the role of KOR-mediated arrestin signaling.  
The Roth Lab recently developed a KOR-based DREADD by mutating one residue 
within the binding pocket of KOR (D138N) (Fig. 4.2). This point mutation led to greatly 
enhanced sal B potency and abolished endogenous peptide function (Vardy et al., in preparation). 
Additional mutations to this DREADD, such as C315A, could create a G protein biased KOR-
DREADD (Fig. 4.1 and Fig. 4.2). To generate a β-arrestin 2 biased KOR DREADD, we could 
mutate regions within the ICL3 to prevent G protein coupling. These biased DREADDs could be 
used to mimic functionally selective ligands, which might be useful target validation prior to the 
development and optimization of biased ligands.  
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4.6  DETERMINING THE GLOBAL SIGNALING EFFECTS OF BIASED LIGANDS  
GPCR-mediated signaling via G proteins and signaling via β-arrestins has been well 
studied, but few studies have examined the more global downstream effects of GPCR activation. 
It was recently shown that there are several hundred GPCR interacting proteins that might 
mediate additional signaling cascades (Chung et al., 2013; Georgoussi et al., 2012). Few studies 
have examined the entire phosphoproteome after treatment with a β-arrestin-biased ligand. 
Arrestin-mediated signaling via the angiotensin type II 1a receptor was examined using a 
combination of a phospho-antibody array and mass spectrometry-quantitative phosphoproteome, 
and the results revealed that 171 proteins showed an increase in phosphorylation and 53 proteins 
showed a decrease in phosphorylation after drug treatment (Xiao et al., 2010). This system-based 
study highlighted the large impact that arrestin-mediated signaling could have on the 
phosphoproteome and provided additional pathways to study. This study did not compare an 
unbiased ligand to the arrestin biased ligand here, but it is likely that there is some crosstalk 
between G protein signaling and arrestin signaling. To further understand which cellular effects 
are mediated by arrestin signaling vs. G protein signaling, a similar study could be performed to 
compare a G protein biased ligand, an arrestin biased ligand, and an unbiased ligand.  
It would be interesting to compare a number of unbiased ligands in this type of analysis 
because these ligands might differentially activate an uncharacterized signaling cascade. There is 
some evidence for KOR-mediated G protein and arrestin-independent activation of c-Jun N-
terminal kinase (JNK) (Bruchas et al., 2007b; Melief et al., 2011). A global phosphoproteomic 
study might provide insight into what additional proteins might be involved in this novel 
signaling pathway.  
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 In addition to understanding how biased ligands differentially affect the 
phosphoproteome, it will be useful to investigate how these ligands impact the transcriptome 
over time. If biased ligands are going to be used for therapeutics, they will likely be administered 
to patients over a chronic, rather than acute, timeframe. Chronic or extended treatment with a 
biased ligand could have unexpected effects on the transcriptome that contribute to altered 
cellular function. Fully understanding how drugs alter cellular functioning is necessary to form 
accurate hypotheses regarding the treatment of disease states.  
4.7  FINAL THOUGHTS 
G protein-coupled receptors are membrane proteins that activate G proteins, but it has 
become increasingly appreciated that the activation of G proteins is only one aspect of GPCR 
function. Because of the expanded GPCR functions, the terminology of these receptors is being 
questioned, and referring to these receptors as seven transmembrane receptors (7TM) is more 
appropriate.  
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Table 4.1: Functional results of C315A point mutation in KOR 
 
Receptor 
Salvinorin A 
G protein (Glo Sensor) 
 
Arrestin 
(BRET) 
 
Bias Factor 
Of Mutation 
WT 5.6 nM 
-8.25 +/- 0.06 
4.29 nM 
-8.37 +/- 0.04 
1 
C315A 8.22 nM 
-8.09 +/- 0.05 
95.8 nM 
-7.02 +/- 0.03 
15 
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Figure 4.1: Results of Salvinorin A function on a KOR mutant receptor 
 (A) G protein signaling of C315A mutant and WT KOR stimulated with sal A, previously 
published in Vardy et al., 2013. (B) β-arrestin 2 mobilization upon sal A stimulation in C315A and 
WT KOR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Location of residues within or around KOR binding pocket  
for mutational analysis 
 The residues highlighted may be useful in identifying the molecular determinants of KOR 
functional selectivity. The structure shown was obtained by Wu et al., 2012. 
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